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Abstract  41 
This clinical practice guideline provides an approach to the treatment of breakthrough 42 
chemotherapy>induced nausea and vomiting (CINV) and the prevention of refractory CINV in 43 
children. It was developed by an international, inter>professional panel and is based on 44 
systematic literature reviews. Evidence>based interventions for treatment of breakthrough and 45 
prophylaxis of refractory CINV are recommended. Gaps in the evidence used to support the 46 
recommendations made in this clinical practice guideline were identified. The contribution of 47 
these recommendations to breakthrough and refractory CINV control in children requires 48 
prospective evaluation. 49 
 50 
 51 
 52 
  53 
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 

54 
Children commonly experience chemotherapy>induced nausea and vomiting (CINV) despite 55 
administration of modern, guideline>consistent antiemetic agents.   Children who experience 56 
CINV in previous chemotherapy blocks despite administration of prophylaxis (breakthrough 57 
CINV) which does not respond to treatment or to changes in CINV prophylaxis are deemed to 58 
have refractory CINV.  Achieving complete CINV control may be more difficult in these 59 
patients[1] and finding effective antiemetic interventions for them can be challenging.  An 60 
evidence>based approach to optimizing CINV control in these patients is therefore essential. 61 
 62 
The overall objective of this clinical practice guideline is to optimize breakthrough and 63 
refractory CINV control in children.  This guideline applies to children aged 1 month to 18 years 64 
receiving chemotherapy.  The target users of this guideline are all healthcare providers who care 65 
for these children.  For the purpose of this guideline, optimal control of breakthrough CINV is 66 
defined as acute relief of nausea or vomiting during the current chemotherapy block.  Optimal 67 
control of refractory CINV is defined as no vomiting, no retching, no nausea, no use of 68 
antiemetic agents other than those given for CINV prevention and no nausea>related change in 69 
the child’s usual appetite and diet. 70 
 71 
This guideline represents the fourth guideline in a series to address CINV in children.  The three 72 
previously published guidelines address chemotherapy emetogenicity, prevention of acute 73 
CINVand management of anticipatory CINV in children with cancer.[2>4] Complete versions of 74 
all four guidelines may be viewed at: http://www.pogo.ca/healthcare/practiceguidelines/.  Our 75 
recommendations are based on the assumption that children are receiving CINV prophylaxis that 76 
is consistent with the previously published guidelines.  77 
 78 
!
79 
Guideline panel and development of clinical questions 80 
Guideline panel members were chosen to represent inter>professional staff from Pediatric 81 
Oncology Group of Ontario centers and from internationally recognized experts in pediatric 82 
supportive care. Once chosen, the panel members developed the specific health questions (Table 83 
I) to be addressed by this guideline.  84 
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 85 
Systematic literature searches 86 
In March 2015, computerized searches (Supplementary Table I) were performed with the 87 
assistance of a library scientist to identify guidelines which could be endorsed for the treatment 88 
of breakthrough CINV and for the prevention of refractory CINV in children. 4,451 citations 89 
were identified and screened. Since none met the inclusion criteria (Table II) for endorsement 90 
assessment, the guideline panel proceeded to develop a  guideline. Systematic reviews of 91 
primary studies evaluating interventions for the treatment of breakthrough CINV and the 92 
prevention of refractory CINV were conducted.   93 
 94 
Evidence identification and synthesis 95 
We searched for primary studies pertinent to the guideline topics (Supplementary Tables II and 96 
III) as of March 13, 2015.  Eligibility was not restricted by age or language. All primary study 97 
designs, except single case reports were eligibile. Citations were screened independently by two 98 
reviewers. Conflicts were resolved by a third. Potentially relevant citations were included for 99 
full>text screening. Two reviewers independently evaluated the full>text papers to determine 100 
whether they met the inclusion criteria (Table II). Disagreements were resolved by a third 101 
reviewer.  Evidence tables were compiled.  102 
 103 
During the guideline development process, it became apparent that understanding the safety of 104 
specific medications in children with cancer was required to better inform recommendations. 105 
Therefore systematic reviews evaluating the safety of metoclopramide[5] and 106 
prochlorperazine[6] were undertaken, and an existing systematic review of the safety of 107 
olanzapine[7] in children was considered by the panel.  Primary studies relating to the safety of 108 
methotrimeprazine in children were also searched (Supplementary Table III) as of March 9, 2015 109 
with the assistance of a library scientist.  Citations were screened, full>text papers were evaluated 110 
to determine if they met the inclusion criteria (Table II) and evidence summary tables were 111 
compiled as described above. 112 
 113 
Decisions were taken through panel discussions; any differences in opinion were resolved by 114 
consensus.  The quality of evidence and strength of recommendations were assessed using the 115 
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GRADE system.[8,9] In formulating recommendations, health benefits, adverse effects and risks 116 
were explicitly considered. 117 
 118 
External review and consultation process 119 
The draft guideline underwent a two>stage external review: first by international experts in CINV 120 
and then by stakeholders from the Ontario pediatric oncology community. Six content experts 121 
provided a review; their comments were discussed in detail by the panel and a decision on each 122 
point was taken by consensus.  Ten Ontario pediatric oncology stakeholders also provided 123 
comments. These identified the need to development guideline implementation tools. 124 
125 
Procedure for updating the guideline 126 
This guideline will be formally updated five years from publication or earlier should new, 127 
significant evidence become available. 128 
129 
130 
A total of 4,654 references were identified from the database searches. Of these, 116 papers were 131 
reviewed in full>text and 59 (breakthrough CINV: 13; refractory CINV: 46) satisfied the 132 
eligibility criteria (Figure 1) and were included in the systematic review.133 
134 
"#
$%&'


(
 135 
) 136 
Breakthrough CINV is defined as nausea and/or vomiting presumed to be attributable to 137 
antineoplastic chemotherapy and with no other pathological cause which occurs during the acute 138 
or delayed phase despite CINV prophylaxis. 139 
 140 
No studies were identified that described the treatment of breakthrough CINV exclusively in 141 
children.  Thirteen studies in adults met criteria for inclusion (four randomized trials, two non>142 
randomized comparative studies, and seven prospective single arm studies).  143 
 144 
Evidence describing the treatment of breakthrough CINV in adults is summarized in 145 
Supplementary Table IV.  The guideline recommendations are summarized in Table I.  Studies 146 
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evaluating ABH gel, 5>HT3 antagonists and  prochlorperazine were included in the evidence 147 
summary but were omitted from the recommendations due to poor systemic bioavailability,[10] 148 
inclusion as standard acute CINV prophylaxis[11] and safety concerns,[6] respectively. 149 
 150 


%*%:For children receiving acute CINV prophylaxis recommended for 151 
minimally, low, or moderately emetogenic chemotherapy, clinicians should upgrade or escalate 152 
the acute CINV prophylaxis provided to that recommended for chemotherapy of the next higher 153 
level of emetogenic risk.  154 
 155 
No specific evidence was identified that evaluated the escalation of CINV prophylaxis as 156 
treatment for breakthrough CINV in children.  This recommendation is grounded in the evidence 157 
supporting the interventions recommended for acute CINV prophylaxis in children. [11] 158 
 159 
This recommendation places a high value on the possible control of breakthrough CINV in the 160 
acute phase by providing antiemetic interventions (pharmacological and non>pharmacological) 161 
known to be effective in the setting of more emetogenic chemotherapy. It is a strong 162 
recommendation because the panel is certain that the benefits of acute CINV prophylaxis 163 
escalation outweigh the low risk of harms associated with these interventions. 164 
165 


%*+: For children receiving acute CINV prophylaxis recommended for highly 166 
emetogenic chemotherapy (HEC), we suggest that olanzapine be added to guideline>consistent 167 
CINV prophylaxis. 168 
 169 
Adult Patients  170 
Two primary studies evaluated the use of olanzapine for the treatment of breakthrough 171 
CINV.[12,13]  In a double>blind, randomized controlled trial, Navari et al evaluated the efficacy 172 
of olanzapine vs. metoclopramide for the treatment of breakthrough CINV in adult 173 
chemotherapy>naive patients receiving HEC and CINV prophylaxis with palonosetron, 174 
dexamethasone and fosaprepitant.[13]  At the onset of breakthrough CINV, patients were 175 
randomized to receive olanzapine (10 mg orally daily for three days) or metoclopramide (10 mg 176 
orally TID for three days).   Dexamethasone was stopped when olanzapine or metoclopramide 177 
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was initiated.  The proportions of patients achieving complete control of breakthrough vomiting 178 
over the 72 hour observation period in the olanzapine and metoclopramide arms were 70% and 179 
31% (p < 0.01), respectively.  Similarly, a greater proportion of patients who received olanzapine 180 
(68%) achieved complete control of nausea compared to those patients receiving 181 
metoclopramide (23%, p < 0.01).  182 
183 
Chanthawong et al described the efficacy of olanzapine for the treatment of breakthrough 184 
vomiting in adults receiving moderately emetogenic chemotherapy (MEC) or HEC.[12]  In this 185 
prospective, open>label study, olanzapine (5 mg orally q12h for two doses) was administered to 186 
patients experiencing breakthrough emesis despite prophylaxis with ondansetron, a 187 
corticosteroid, and metoclopramide.  Complete control of breakthrough vomiting was 188 
experienced by 28 of 46 patients (61%) after olanzapine administration.  Nausea was not 189 
evaluated. 190 
 191 
No clinically significant adverse effects were reported in either study that evaluated olanzapine 192 
for the treatment of breakthrough CINV in adults.  Dizziness, fatigue, and dyspepsia, described 193 
as mild and tolerable, were reported by Chanthawong et al.[12] 194 
 195 
Pediatric Patients 196 
No pediatric studies of olanzapine for the treatment of breakthrough CINV were identified from 197 
the literature search. The guideline panel is aware of one recent paper, published after the March 198 
2015 search end>date, which addresses the use of olanzapine in children. This multi>center, 199 
retrospective review described chemotherapy>induced vomiting (CIV) control and adverse 200 
effects in children receiving olanzapine.[14]  In this cohort, 20 children received olanzapine for 201 
breakthrough CINV during 21 chemotherapy blocks.  Complete CIV control was reported the 202 
day following the first olanzapine dose in 12 chemotherapy blocks (57%). Nausea control was 203 
not assessed. 204 
 205 
In a systematic review and meta>analysis, weight gain and sedation (78% (95% confidence 206 
interval (CI): 63 to 95%) and 48% (95% CI: 35 to 67%), respectively) were commonly 207 
associated with the use of olanzapine in children less than 13 years old.[7]  Extrapyramidal 208 
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symptoms (EPS) and electrocardiograph abnormalities were reported less frequently (9% (95% 209 
CI: 4 to 21%) and 14% (95% CI: 7 to 26%), respectively).  Most adverse effects associated with 210 
olanzapine use were of minor clinical significance; no fatalities attributable to olanzapine were 211 
identified.   212 
 213 
This recommendation is consistent with adult guidelines for the treatment of breakthrough CINV 214 
in adult cancer patients.[15,16]  It places value on the high quality evidence of the efficacy of 215 
olanzapine in adults receiving contemporary CINV prophylaxis.  It is a weak recommendation 216 
because direct evidence of efficacy of olanzapine for prevention or treatment of CINV in 217 
children and of its safety in children receiving chemotherapy is limited or indirect.  Furthermore, 218 
the optimal pediatric dose for this indication is uncertain.  It may be reasonable to give 219 
olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) once daily by mouth. This dose is based on 220 
the results of the retrospective review[14] and uses the adult dose as the maximum dose. If CINV 221 
is not controlled and sedation does not occur or is not troublesome, the dose could potentially be 222 
increased to 0.14 mg/kg/dose (maximum 10 mg/dose).  Olanzapine injection should not be 223 
administered for CINV control since it has not been evaluated for this indication.  Olanzapine 224 
should be avoided in patients receiving CYP1A2 inducers (e.g. carbamazepine, rifampin) or 225 
inhibitors (e.g. ciprofloxacin, fluvoxamine) as olanzapine is primarily metabolized via this 226 
enzymatic pathway.[17]   227 
228 


%*,&For children receiving acute CINV prophylaxis recommended for HEC 229 
and who cannot receive olanzapine, we suggest that 
 of the following antiemetic agents be 230 
added to guideline>consistent CINV prophylaxis: methotrimeprazine (also known as 231 
levomepromazine) 
metoclopramide (in children older than 1 year)232 
 233 
	
	

 234 
Adult Patients  235 
One prospective open>label study was identified which evaluated methotrimeprazine for the 236 
treatment of breakthrough CINV in 32 patients.  McCabe at al evaluated the efficacy of a single 237 
25 mg subcutaneous dose of methotrimeprazine for the treatment of breakthrough CINV 238 
occurring in the delayed phase in adult cancer patients receiving HEC.[18]  The proportion of 239 
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patients achieving complete control of breakthrough vomiting over the first 24 and 48 hours of 240 
methotrimeprazine administration was 88% and 94%, respectively.  The proportion of patients 241 
achieving complete control of breakthrough nausea in 24 and 48 hours with administration of 242 
methotrimeprazine was 75% and 94%, respectively.   243 
 244 
Drowsiness, dry mouth, and constipation are the most commonly reported adverse effects of 245 
methotrimeprazine in adult psychiatric patients[19]. Sedation (12/32 patients), hypotension 246 
(8/32), and induration at the site of methotrimeprazine administration (32/32) were the most 247 
commonly reported adverse effects experienced by patients included in the previously described 248 
study. [18] 249 
 250 
Pediatric Patients 251 
No evidence was identified that described the use of methotrimeprazine in children for the 252 
treatment of breakthrough CINV.  Despite being licensed for use in children in Canada,[19] 253 
information regarding the use of methotrimeprazine in pediatric patients for any indication is 254 
limited.  The pediatric dose recommended by the manufacturer is 0.25 mg/kg/day by mouth in 2 255 
or 3 divided doses initially and increasing to a maximum of 40 mg/day in children 12 years of 256 
age or less.[19]  257 
 258 
Four studies (two retrospective reviews, 1 case series and 1 case report) involving 30 children 259 
were included in a systematic review of the safety of methotrimeprazine in children 260 
(Supplementary Table V).  No persistent adverse effects or fatalities were attributable to 261 
methotrimeprazine in these studies. 262 
263 
	
	
 264 
Adult Patients 265 
Two studies (a randomized controlled trial and a prospective observational study) were included. 266 
The randomized trial evaluating the efficacy of olanzapine vs. metoclopramide for the treatment 267 
of breakthrough CINV in chemotherapy>naive adults receiving HEC has been described 268 
previously.[13]  Musso et al also evaluated the efficacy of metoclopramide (20 mg IV q6h or 269 
q12h) vs. a second dose of palonosetron (0.25 mg IV) in adults receiving either MEC or 270 
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HEC.[20] Patients assigned to the metoclopramide arm received prophylaxis with ondansetron 271 
plus dexamethasone, while those in the palonosetron group received palonosetron plus 272 
dexamethasone.  The proportion of patients achieving complete control of breakthrough CINV in 273 
the metoclopramide group was 22%, vs. 67% in the palonosetron group (p = 0.039).  274 
 275 
Navari et al[13] reported no grade 3 or 4 toxicities attributable to metoclopramide  and Musso et 276 
al stated that no serious adverse events observed in their study were attributable to antiemetic 277 
treatment.[20] 278 
 279 
Pediatric Patients 280 
No evidence was identified that described the use of metoclopramide exclusively in pediatric 281 
patients for the treatment of breakthrough CINV. However, it is recommended for acute CINV 282 
prophylaxis in children as an alternate to dexamethasone.[11]   283 
 284 
In a recent systematic review and meta>analysis of adverse effects of metoclopramide in 285 
children, the mean proportion of children reported to have EPS was 9% (95% CI: 5 to 17%) or 286 
diarrhea was 6% (95% CI: 3 to 9%).[5]  In single>dose and multiple>dose metoclopramide 287 
studies, the mean proportion of children reported to experience sedation was 2% (95% CI: 1 to 288 
5%) and 6% (95% CI: 3 to 12%), respectively.  Since Health Canada and the European 289 
Medicines Agency have recently issued warnings regarding the risk of EPS in young children 290 
receiving metoclopramide, the panel recommends that metoclopramide be avoided in children 291 
less than 1 year old[21].   292 
 293 
Methotrimeprazine is a phenothiazine similar to chlorpromazine. It is marketed in Canada, 294 
Europe, and Australia.   Current CINV prophylaxis guidelines recommend the use of 295 
metoclopramide for the treatment of breakthrough CINV in adults.[15,16] The panel recognizes 296 
that the evidence base for these agents consists of studies in adults that were not conducted in the 297 
context of currently recommended CINV prophylaxis.  Despite these limitations and although 298 
direct evidence of efficacy of these agents for treatment of breakthrough CINV in children is not 299 
available, the guideline panel placed a high value on the possible benefit of these agents in the 300 
setting of breakthrough CINV. A lower value was placed on the potential for toxicity secondary 301 
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to these agents because EPS are generally amenable to intervention and, although possibly 302 
distressing if not anticipated, are short>lived.   303 
 304 
"#
$+&'


 305 

	
 )  306 
Refractory CINV is defined as nausea and/or vomiting presumed to be attributable to 307 
antineoplastic chemotherapy and with no other pathological cause which occurs during the acute 308 
or delayed phase despite CINV prophylaxis in patients who have experienced breakthrough 309 
CINV in a previous chemotherapy block.310 
 311 
Two studies were identified that described the prevention of refractory CINV in children: one 312 
prospective study evaluating the use of tropisetron[22] and a retrospective review evaluating the 313 
use of aprepitant.[23]  Forty>one studies in adults met criteria for inclusion in this evidence base 314 
(five randomized trials, four non>randomized prospective comparative studies, 31 prospective 315 
single arm studies, and one case series). Evidence describing the prevention of refractory CINV 316 
in children and adults is summarized in Supplementary Table VI.  Dexamethasone, 317 
tetrahydrocannabinol, levonantradol, Sancuso®, benzodiazepines, medroxyprogesterone, 318 
nabilone and propofol were included in the evidence summary but were omitted from the 319 
recommendations.  Similarly, placebo>controlled trials, dosage form comparison studies or single 320 
arm studies evaluating 5>HT3 antagonists other than palonosetron were omitted from the 321 
recommendations. This decision was taken for one or more of the following reasons: 1) the agent 322 
is currently recommended for acute CINV prophylaxis; 2) it is not available in a dosage form 323 
suitable for pediatric use; 3) outcome data have only been reported in an extremely small number 324 
of patients; 4) there is a lack efficacy data in the context of modern CINV prophylaxis or 5) the 325 
agent is difficult to administer safely. 326 
 327 


+*%&For children receiving acute CINV prophylaxis recommended for 328 
minimally, low, or moderately emetogenic chemotherapy, clinicians should upgrade or escalate 329 
the acute CINV prophylaxis provided to that recommended for chemotherapy of the next higher 330 
level of emetogenic risk.  331 
332 
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No specific evidence was identified that evaluated the escalation of CINV prophylaxis as a 333 
preventative measure for refractory CINV in children.  The panel felt that escalation of 334 
prophylaxis is a logical approach that is grounded in the evidence described previously in 335 
Recommendation 1.1. 336 
337 
This recommendation places a high value on the possible control of refractory CINV in the acute 338 
phase by provision of acute CINV prophylaxis (pharmacological and non>pharmacological) 339 
known to be effective in the setting of more emetogenic chemotherapy. It is a strong 340 
recommendation because the guideline panel is certain that the benefits of acute CINV 341 
prophylaxis escalation outweigh the low risk of harms associated with the interventions. 342 
343 


+*+&For children receiving acute CINV prophylaxis recommended for HEC, 344 
we suggest that the 5>HT3 antagonist given for CINV prophylaxis be changed from ondansetron 345 
or granisetron to palonosetron. In jurisdictions where palonosetron is not available, we suggest 346 
that granisetron be substituted for ondansetron.347 
 348 
	


349 
Adult Patients 350 
Two prospective open>label studies were identified. The first evaluated the efficacy and safety of 351 
a single IV dose of palonosetron in adults receiving chemotherapy with low emetogenic potential 352 
who had experienced refractory CINV.[24]  Complete acute CINV control was achieved in 29 of 353 
34 (85.3%) patients.  A second study evaluated the efficacy of palonosetron in preventing 354 
refractory CINV in adults who had previously received CINV prophylaxis with either 355 
granisetron or ondansetron.[25]  Complete CINV control rates in the acute and delayed phases of 356 
77% and 81% were observed, respectively.  The most commonly reported adverse effects 357 
reported by patients in this study were constipation and anxiety; no patient experienced severe 358 
toxicity.  359 
 360 
Pediatric Patients 361 
No evidence was identified that described switching from ondansetron or granisetron to 362 
palonosetron in children for the prevention of refractory CINV. Palonosetron was recently 363 
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approved for use in pediatric patients in the United States for prevention of acute CINV as a 364 
single dose of 20 µg/kg (max 1.5 mg) prior to chemotherapy[26]. The limited, peer>reviewed, 365 
published evidence to support its use in children has been summarized previously.[11]  366 
 367 
This recommendation is consistent with adult guidelines related to palonosetron since it is 368 
considered the 5>HT3 antagonist of choice in adults receiving MEC.[15,27]It places a high value 369 
on the improved CINV control seen in adult cancer patients receiving palonosetron.  It places 370 
less value on drug cost in the scenario where less expensive alternatives have been ineffective. It 371 
is a weak recommendation because direct evidence of the comparative efficacy of palonosetron 372 
for prevention of refractory CINV in children is not available.  However, the available 373 
information (including approval by the US Food and Drug Administration for the prevention of 374 
CINV in children) indicates that palonosetron can be used safely in pediatric cancer patients.  375 
 376 
	

377 
Either ondansetron or granisetron is recommended for acute CINV prophylaxis in all children 378 
receiving chemotherapy of low, moderate or high emetogenic risk.[11]  There is no evidence to 379 
support use of one first generation 5>HT3 receptor antagonist over the other in children. 380 
However, ondansetron is primarily metabolized via the cytochrome P450 CYP 2D6 enzyme and 381 
studies in adults have shown that polymorphisms in this enzyme predispose patients to poor 382 
CINV control secondary to rapid ondansetron metabolism.[28]  383 
 384 
Adult Patients 385 
A single study was identified that evaluated the efficacy of granisetron after CINV failure while 386 
receiving ondansetron in adults receiving HEC.[29] The authors reported complete CINV control 387 
(no vomiting and no or mild nausea) in 47% (9/19) of patients who received granisetron while 388 
only 5% (1/21) of patients who continued to receive ondansetron experienced complete CINV 389 
control (p = 0.005).   390 
 391 
Pediatric Patients 392 
No evidence was identified that described switching from ondansetron to granisetron in children 393 
for the prevention of refractory CINV.  394 
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 395 
If palonosetron is not available, it is suggested that granisetron be substituted for ondansetron in 396 
patients who experienced refractory CINV while receiving ondansetron.  This recommendation 397 
is based on the potential for genetic variability in the enzymes responsible for metabolizing 398 
ondansetron. It places a high value on the improved CINV control seen in adult cancer patients 399 
receiving granisetron who have a genetic predisposition to a poor response to ondansetron at 400 
usual doses.  It places less value on drug cost in the scenario where a less expensive alternative 401 
has been ineffective. It is a weak recommendation because direct evidence of using an alternative 402 
5HT>3 antagonist for prevention of refractory CINV in children is not available.   403 
404 


+*,&For children experiencing refractory CINV despite initiation of previous 405 
recommendations and who have not previously received aprepitant because it is known or 406 
suspected to interact with the chemotherapeutic agent(s) being given, we suggest that the 407 
addition of aprepitant to acute CINV prophylaxis be considered. 408 
409 
The use of aprepitant is currently recommended for acute CINV prophylaxis in children greater 410 
than or equal to 12 years of age receiving HEC which is not known or suspected to interact with 411 
this agent[11] and recent evidence supports its use in children as young as 6 months.[30]  412 
Aprepitant is a CYP3A4 substrate and an inhibitor of CYP2C9/8 and CYP2C19.  As a result, it 413 
may potentially interact with medications, including chemotherapy, metabolized via these 414 
pathways.  The issues which must be considered when using aprepitant in pediatric patients have 415 
been summarized previously.[11]  Interactions with chemotherapy which may lead to an 416 
increased risk of short and long>term toxicity are of primary concern. However, direct evidence 417 
of these interactions is often unavailable and interpretation of the results of available studies that 418 
do evaluate aprepitant/fosaprepitant interactions with chemotherapy varies.419 
 420 
Adult Patients 421 
Six prospective, open>label studies were identified that evaluated the use of aprepitant in adults 422 
with refractory CINV receiving MEC or HEC.  Since guidelines for CINV prophylaxis in adult 423 
cancer patients now recommend the use of aprepitant or its intravenous pro>drug fosaprepitant, 424 
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as prophylaxis for HEC and for some MEC regimens,[15,16,27]  studies of aprepitant for 425 
breakthrough CINV will not be discussed since this approach is no longer applicable. 426 
 427 
Pediatric Patients 428 
One study was identified describing the use of aprepitant in children and adolescents with 429 
refractory CINV.[23]  Bauters et al retrospectively evaluated the addition of aprepitant using the 430 
recommended adult dose (125 mg on day one prior to chemotherapy followed by 80 mg once 431 
daily on days 2 and 3) to a 5>HT3 antagonist plus dexamethasone in 20 patients 8 > 16 years of 432 
age during 104 MEC or HEC blocks.  Complete control of vomiting in the acute phase was 433 
achieved in 86% of chemotherapy blocks.  The authors described aprepitant as well>tolerated in 434 
combination with other antiemetics. 435 
  436 
Additional expereince with the use of aprepitant in adolescents is summarized in the pediatric 437 
acute CINV prophylaxis guideline.[11]  Information regarding the use of aprepitant in younger 438 
children is growing and it is now approved in the US for use in children 6 months of age and 439 
older.[30>35] Published experience with fosaprepitant in children is limited[36].  440 
441 
This recommendation places a high value on improved CINV control when control is likely to be 442 
difficult to achieve and on the negative consequences of uncontrolled CINV.  It is a weak 443 
recommendation since direct evidence of the efficacy of aprepitant in this context is lacking.  444 
The potential improvement in CINV control offered by the addition of aprepitant should be 445 
weighed against the short and long>term toxicities resulting from potential interactions with 446 
chemotherapy.  It is essential to include the patient, when appropriate, and family in this 447 
discussion so their values can be incorporated into the decision>making process.  The relative 448 
risks of aprepitant (potential for drug interaction with chemotherapy and altered chemotherapy 449 
exposure) and benefits (CINV control) should be determined on a case>by>case basis. 450 
 451 


 +*-& For children experiencing refractory CINV despite initiation of the 452 
previous recommendations, we suggest that 
 of the following interventions be added to the 453 
CINV prophylaxis provided:interventions that were employed successfully for the treatment of 454 
breakthrough CINV in previous treatment blocks (olanzapine, methotrimeprazine or 455 
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metoclopramide) or stimulation of Nei Guan (P6) by means of acupressure or electro>456 
acupuncture.457 
458 



	


  459 
No specific evidence was identified that evaluated the efficacy of incorporating successful 460 
breakthrough CINV interventions from previous treatment blocks into the CINV prophylaxis 461 
provided for future chemotherapy blocks in children.  Again, the panel felt that this is a logical 462 
approach and is another example of providing individualized care for patients.  Olanzapine has 463 
been recommended for the treatment of breakthrough CINV in Recommendation 1.2.  For 464 
children who cannot receive olanzapine, methotrimeprazine and metoclopramide have been 465 
recommended. In one study,[37] 62% of adults with refractory CINV achieved complete CINV 466 
control after administration of methotrimeprazine. 467 
 468 
This recommendation places a high value on the potential for CINV control using interventions 469 
that are recommended for the treatment of breakthrough CINV and that were used successfully 470 
and without significant adverse effects in patients who previously experienced breakthrough 471 
CINV.  It is a weak recommendation because the impact of the recommended action has not 472 
been evaluated. 473 
 474 




475 
Adult Patients 476 
One study evaluating the use of acupressure, [38] and another evaluating the use of electro>477 
acupuncture[39] in adults with cancer were identified.  Both were prospective, open>label studies 478 
of Nei Guan (P6) stimulation.  It was not possible to determine if the CINV prophylaxis given in 479 
combination with acupressure was consistent with contemporary recommendations.  However, 480 
68% of patients had complete control of vomiting. Combining electro>acupuncture with CINV 481 
prophylaxis consistent with contemporary recommendations resulted in complete vomiting 482 
control in 37% of adult patients.  483 
 484 
  485 
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Pediatric patients 486 
No evidence was identified that described the use of acupressure or electroacupuncture in 487 
children for the prevention of refractory CINV.  488 
 489 
This recommendation places a high value on the possibility that acupressure or acupuncture may 490 
increase control of CINV in patients who have experienced refractory CINV with a low potential 491 
for harm.  It is a weak recommendation because there is a single study to support the use of each 492 
intervention in adults and there is no direct information regarding the efficacy or safety of 493 
acupressure/acupuncture in children with refractory CINV.  494 
495 
496 
The gaps in the evidence available to support recommendations for the control of breakthrough 497 
and refractory CINV in children are substantial.  Examples are provided in Table III. 498 
 499 


500 
Recommendations for the treatment of breakthrough CINV and prevention of refractory CINV in 501 
children are summarized in Table I.  These recommendations are based on a systematic review of 502 
the literature.  However, there are many gaps in the available evidence.  Optimization of CINV 503 
control in children requires delivery of care based on the best available evidence and the 504 
prospective evaluation of both new and old antiemetic agents.      505 
 506 
.
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TABLE I:  Health questions and summary of recommendations for the treatment of breakthrough 
chemotherapy-induced nausea and vomiting (CINV) and the prevention of refractory CINV in children.  A 
recommendation summary table that includes the remarks for each recommendation is presented in 
Supplementary Table VII. 
 
 
Health Questions and Recommendations 
Strength of 
Recommendation 
& Level of 
Evidence
9,10
 
Health Question #1:  What interventions are recommended to treat breakthrough CINV in 
children?  
Breakthrough CINV is defined as nausea and/or vomiting presumed to be attributable to antineoplastic 
chemotherapy and with no other pathological cause which occurs during the acute or delayed phase despite CINV 
prophylaxis. 
 
Recommendation 1.1: For children receiving acute CINV prophylaxis 
recommended for minimally, low, or moderately emetogenic 
chemotherapy, clinicians should upgrade or escalate the acute CINV 
prophylaxis provided to that recommended for chemotherapy of the next 
higher level of emetogenic risk.  
 
Recommendation 1.2: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy, we suggest that 
olanzapine be added to guideline-consistent CINV prophylaxis. 
 
 
Recommendation 1.3: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy and who cannot 
receive olanzapine,  we suggest that one of the following antiemetic 
agents be added to guideline-consistent CINV prophylaxis: 
 
 methotrimeprazine (also known as levomepromazine) 
or 
 metoclopramide (in children older than 1 year) 
 
Given the possibility of extrapyramidal reactions with these agents, 
the risks and benefits of their use should be weighed carefully and 
co-administration of prophylaxis aimed at preventing 
extrapyramidal symptoms (EPS) should be considered. Patients and 
families should also be educated about the possible occurrence of 
EPS. 

 
 
Strong 
Recommendation 
Very Low Quality 
Evidence 
 
 
Weak 
Recommendation 
 Low Quality 
Evidence 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
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Health Question #2:  What interventions are recommended to prevent CINV in children who 
have refractory CINV?   
Refractory CINV is defined as nausea and/or vomiting presumed to be attributable to antineoplastic chemotherapy 
and with no other pathological cause which occurs during the acute or delayed phase despite CINV prophylaxis in 
patients who have experienced breakthrough CINV in a previous chemotherapy block.  
 
Recommendation 2.1:  For children receiving acute CINV prophylaxis 
recommended for minimally, low, or moderately emetogenic 
chemotherapy, clinicians should upgrade or escalate the acute CINV 
prophylaxis provided to that recommended for chemotherapy of the next 
higher level of emetogenic risk.   
 
Recommendation 2.2: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy, we suggest that the 
5-HT3 antagonist given for CINV prophylaxis be changed from 
ondansetron or granisetron to palonosetron. In jurisdictions where 
palonosetron is not available, we suggest that granisetron be substituted 
for ondansetron. 
 
Recommendation 2.3: For children experiencing refractory CINV despite 
initiation of previous recommendations and who have not previously 
received aprepitant because it is known or suspected to interact with the 
chemotherapeutic agent(s) being given, we suggest that the addition of 
aprepitant to acute CINV prophylaxis be considered.  
 
Recommendation 2.4: For children experiencing refractory CINV despite 
initiation of the previous recommendations, we suggest that one of the 
following interventions be added to the CINV prophylaxis provided: 
 
 interventions that were employed successfully for the treatment 
of breakthrough CINV in previous treatment blocks (olanzapine, 
methotrimeprazine or metoclopramide); or 
 
 
 stimulation of Nei Gaun (P6) by means of acupressure or electro-
acupuncture. 
 
Strong 
Recommendation 
Very Low Quality 
Evidence 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
 
 
 
Weak 
Recommendation 
Low Quality 
Evidence 
 
 
 
 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
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TABLE II: Study inclusion criteria for three systematic reviews undertaken 
Guidelines 
(i) provided recommendations specifically for the management of breakthrough and/or 
refractory CINV;  
(ii) were published in 2012 or more recently;  
(iii) were based on a systematic review of the literature and  
(iv) were published in English. 
Treatment of breakthrough CINV and prevention of CINV in patients who have experienced 
refractory CINV 
(i) were primary studies, other than single case reports;  
(ii) were either fully published studies (no date restriction) or conference abstracts published in 
2011 or more recently;  
(iii) evaluated an intervention to treat breakthrough CINV or prevent CINV in refractory patients;  
(iv) for prevention interventions: reported the proportion of patients experiencing complete 
control of CINV in refractory patients; and  
(v) for treatment interventions: described the  response to the first dose of the breakthrough 
treatment (ideally within the first 24 hrs after administration) as a proportion of patients 
experiencing complete control or/and during the remainder of the phase in question 
(acute/delayed). 
Safety of methotrimeprazine in children 
(i) published in English in a journal in full text or a letter to the editor reporting primary data;  
(ii) included patients ≤18 years of age and either results were reported separately for patients ≤18 
years of age or the mean or median age pf participants was  ≤18 years;  
(iii) described the adverse effects associated with the use of methotrimeprazine; and  
(iv) the methotrimeprazine dose used was provided or, in the case of poisoning where the dose 
ingested was not able to be determined, a blood methotrimeprazine concentration was 
reported.  
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TABLE III:  Examples of research gaps identified in the domain of treatment of breakthrough 
chemotherapy-induced nausea and vomiting and the prevention of refractory CINV in children 
 
Domain Issues 
Breakthrough CINV  efficacy of CINV prophylaxis escalation 
 optimal dose, efficacy and safety of olanzapine and methotrimeprazine 
 optimal dose, efficacy of metoclopramide and risk factors for toxicity 
Refractory CINV  optimal palonosetron dose in children receiving multiple day chemotherapy 
 extent and clinical significance of interactions between aprepitant and 
chemotherapy 
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Figure 1: Interventions to treat breakthrough CINV or prevent CINV in refractory patients: 
flowchart of literature identification process  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5993 Citations Identified 
1339 Duplicates Removed 
4654 Titles and Abstracts Screened 
4538 Excluded 
116 Full-text Screened 
57 Excluded 
1 Not a primary study other than a single case 
report 
10 Not a fully published paper (no date restriction) 
or a conference abstract published before 2011 
13 Does not evaluate an intervention to treat 
breakthrough CINV or prevent CINV in 
refractory patients  
24 For prevention: Does not report the proportion 
of pts experiencing complete control of 
breakthrough CINV in refractory patients; or for 
treatment: Does not describe response to first 
dose of the breakthrough treatment (ideally 
within 1st 24 hrs after administration) as a 
proportion of patients experiencing complete 
control or/and during the remainder of the 
phase in question (acute/delayed) 
9 Duplicate abstract version of a fully published 
study 
59 Studies Included 
13 Breakthrough CINV Studies 
46  Refractory CINV Studies 
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Supplementary Table I: Guideline Search Strategy 
 
MEDLINE: The search strategy for OvidSP MEDLINE (1946 to March Week 2 2015)  
Set History 
1 exp neoplasms/ or exp Antineoplastic Agents/ or organ transplantation/ or exp tissue transplantation/ or 
transplantation, autologous/ or transplantation, heterologous/ or transplantation, heterotopic/ or exp transplantation, 
homologous/ or (neoplasm* or neoplas* or cancer* or oncolog* or tumor* or tumour* or transplant*).mp. or radiation 
dosage/ or dose-response relationship, radiation/ or Radiometry/ or Radiotherapy Dosage/ or (((gray or sievert) adj2 
unit*) or (radiation adj2 (dosage* or dose or dosing)) or "gy radiation" or "radiation dose-response").mp. or 
chemoradiotherapy/ or chemoradiotherapy, adjuvant/ or Radiotherapy, Adjuvant/ or rt.fs. or radiotherapy/ or 
((adjuvant adj2 chemotherap*) or chemoradiotherap* or radiochemotherap* or cancer* or oncol* or tumour* or 
tumor* or malignan* or neoplas* or sarcom* or blastoma* or neuroblastoma* or leukem* or leukaem * or carcinoma* 
or lymphoma* or adenocarcinoma* or hodgkin* or chemotherap* or radiation*).mp. 
2 (consensus development conference or consensus development conference, nih or guideline or practice guideline).pt. 
or practice guideline/ or guideline/ or guidelines as topic/ or practice guidelines as topic/ or consensus development 
conferences as topic/ or consensus development conferences, nih as topic/ or clinical protocols/ or antineoplastic 
protocols/ or antineoplastic combined chemotherapy protocols/ or Critical Pathways/ or (guideline* or "evidence-based 
recommend*" or "evidence based recommend*").ti,ab.  
3 1 and 2 
4 limit 3 to "all child (0 to 18 years)" 
5 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or toddler* or paediatric* or 
pediatric*).mp 
6 4 or (3 and 5) 
7 limit 3 to ("all adult (19 plus years)" or "all aged (65 and over)" or "aged (80 and over)") 
8  6 not 7 
9 limit 9 to (english language and yr="2012 -Current") 
 
 
EMBASE: The search strategy for OvidSP Embase Classic+Embase (1947 to 2015 Week 10) 
Set History 
1 exp neoplasm/ or exp Antineoplastic Agent/ or organ transplantation/ or stem cell transplantation/ or exp allogeneic 
stem cell transplantation/ or autologous stem cell transplantation/ or exp hematopoietic stem cell transplantation/ or 
mesenchymal stem cell transplantation/ or bone marrow transplantation/ or tissue transplantation/ or allogenic bone 
marrow transplantation/ or autologous bone marrow transplantation/ or bone marrow purging/ or bone marrow 
rescue/ or radiotherapy/ or blood radiation/ or chemoradiotherapy/ or adjuvant chemoradiotherapy/ or radiotherapy/ 
or blood radiation/ or exp chemoradiotherapy/ or exp cobalt therapy/ or image guided radiotherapy/ or intensity 
modulated radiation therapy/ or intraoperative radiotherapy/ or megavoltage radiotherapy/ or radiation depth dose/ 
or radiation dose/ or radiation dose escalation/ or radiation dose fractionation/ or radiation dose reduction/ or 
radiation response/ or radioimmunotherapy/ or radiation measurement/ or dosimetry/ or radiometry/ or (((gray or 
sievert) adj2 unit*) or (radiation adj2 (dosage* or dose or dosing)) or "gy radiation" or "radiation dose-response").mp. 
or rt.fs. or ((adjuvant adj2 chemotherap*) or chemoradiotherap* or radiochemotherap* or cancer* or oncol* or 
tumour* or tumor* or malignan* or neoplas* or sarcom* or blastoma* or neuroblastoma* or leukem* or leukaem* or 
carcinoma* or lymphoma* or adenocarcinoma* or hodgkin* or chemotherap* or radiation*).mp. 
2 practice guideline/ or clinical pathway/ or clinical protocol/ or consensus development/ or good clinical practice/ or 
nursing care plan/ or nursing protocol/ or ((standard adj2 care) or consensus).mp. or (guideline* or "evidence-based 
recommend*" or "evidence based recommend*").ti,ab.  
3 1 and 2 
4 limit 3 to (infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 
years> or adolescent <13 to 17 years>) 
5 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or toddler* or paediatric* or 
pediatric*).mp. 
6 4 or (3 and 5) 
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7 limit 4 to (adult <18 to 64 years> or aged <65+ years>) 
8 6 not 7 
9 limit 8 to (english language and yr="2012 -Current") 
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Supplementary Table II: Search Strategies for Systematic Reviews of primary CINV Studies 
MEDLINE: The search strategy for OvidSP MEDLINE (1946 to March Week 2 2015)  
Set History 
1 exp neoplasms/ or exp Antineoplastic Agents/ or (Chemotherap* adj2 induc*).mp. or CINV.mp. or ci.fs. or 
chemotherap*.mp. 
2 nausea/ or vomiting/ or (emesis or vomit* or retch* or nauseous or nausea*).mp. 
3 ((failure* or failing or subsequent* or rescue* or refractory or breakthrough* or "break-through" or (break adj2 
through*)) adj15 (nause* or vomit* or retch* or antiemetic* or "anti-emetic*" or emesis or emetic* or 
emetogenic*)).mp. 
4 1 and 2 and 3 
 
EMBASE: The search strategy for OvidSP Embase Classic+Embase (1947 to 2015 Week 10)  
Set History 
1 exp *neoplasm/ or exp *Antineoplastic Agent/ or *cancer chemotherapy/ or *cancer combination chemotherapy/ 
2 *"nausea and vomiting"/ or *nausea/ or *retching/ or *vomiting/ or (emesis or vomit* or retch* or nauseous or 
nausea*).mp. 
3 ((failure* or failing or subsequent* or rescue* or refractory or breakthrough* or "break-through" or (break adj2 
through*)) adj15 (nause* or vomit* or retch* or antiemetic* or "anti-emetic*" or emesis or emetic* or 
emetogenic*)).mp. 
4 1 and 2 and 3 
5 "chemotherapy induced nausea and vomiting"/ or chemotherapy induced emesis/ 
6 (failure* or failing or subsequent* or rescue* or refractory or breakthrough* or "break-through" or (break adj2 
through*)).mp. 
7 5 and 6 
8 4 or 7 
 
EBM Reviews - Cochrane Central Register of Controlled Trials: OvidSP EBM Reviews - Cochrane Central Register of 
Controlled Trials < February 2015>  
Set History 
1 exp neoplasms/ or exp Antineoplastic Agents/ or (Chemotherap* adj2 induc*).mp. or CINV.mp. or ci.fs. or 
chemotherap*.mp. or exp *Neoplasms/ or exp *Antineoplastic Agent/ or *cancer chemotherapy/ or *cancer 
combination chemotherapy/ 
2 nausea/ or vomiting/ or (emesis or vomit* or retch* or nauseous or nausea*).mp. or "*nausea and vomiting"/ or 
*nausea/ or *retching/ or *vomiting/ or (emesis or vomit* or retch* or nauseous or nausea*).mp. 
3 ((failure* or failing or subsequent* or rescue* or refractory or breakthrough* or "break-through" or (break adj2 
through*)) adj15 (nause* or vomit* or retch* or antiemetic* or "anti-emetic*" or emesis or emetic* or 
emetogenic*)).mp. 
4 1 and 2 and 3 
5 "chemotherapy induced nausea and vomiting"/ or chemotherapy induced emesis/ 
6 (failure* or failing or subsequent* or rescue* or refractory or breakthrough* or "break-through" or (break adj2 
through*)).mp. 
7 5 and 6 
8 4 or 7 
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Supplementary Table III: Search Strategies for Systematic Reviews of Pediatric Methotrimeprazine 
(Levomepromazine) StudiesCH ATEGIES FOR SYSTEMATIC REVIEWS OF PRIMARY CINV STUDIES 
MEDLINE: The search strategy for OvidSP MEDLINE (1946 to March Week 1 2015)  
Set History 
1 Methotrimeprazine/ or ("apo-methoprazine" or "bayer 1213" or "cl 36467" or "cl 39743" or cl36467 
or cl39743 or hirnamin or methoxyphenothiazine or "l mepromazine" or levium or "levo mepromazine 
" or "levo promazine" or levomeprazine or levomepromazine or levopromazin or levopromazine or 
levoprome or levozin or mepromazine or methotrimeprazine or methotrimperazine or methozane or 
milezin or minozinan or neozine or neuractil or neurocil or nirvan or nozinan or "rp 7044" or rp7044 or 
sinogan or "skf 5116" or skf5116 or tiscerin or tisercin or veractil).mp. 
2 limit 1 to "all child (0 to 18 years)" 
3 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or 
toddler* or paediatric* or pediatric*).mp. 
4  1 and 3 
5 2 or 4 
 
EMBASE: The search strategy for OvidSP Embase Classic+Embase (1947 to 2015 Week 10)  
Set History 
1 levomepromazine/ or ("apo-methoprazine" or "bayer 1213" or "cl 36467" or "cl 39743" or cl36467 or 
cl39743 or hirnamin or methoxyphenothiazine or "l mepromazine" or levium or "levo mepromazine " 
or "levo promazine" or levomeprazine or levomepromazine or levopromazin or levopromazine or 
levoprome or levozin or mepromazine or methotrimeprazine or methotrimperazine or methozane or 
milezin or minozinan or neozine or neuractil or neurocil or nirvan or nozinan or "rp 7044" or rp7044 
or sinogan or "skf 5116" or skf5116 or tiscerin or tisercin or veractil).mp. 
2 limit 1 to (infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school 
child <7 to 12 years> or adolescent <13 to 17 years>) 
3 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or 
toddler* or paediatric* or pediatric*).mp. 
4  1 and 3 
5 2 or 4 
 
EBM Reviews - Cochrane Central Register of Controlled Trials: Wiley Cochrane Library Central Register of Controlled 
Trials < February 2015>  
Set History 
1 levomepromazine/ or ("apo-methoprazine" or "bayer 1213" or "cl 36467" or "cl 39743" or cl36467 or 
cl39743 or hirnamin or methoxyphenothiazine or "l mepromazine" or levium or "levo mepromazine " 
or "levo promazine" or levomeprazine or levomepromazine or levopromazin or levopromazine or 
levoprome or levozin or mepromazine or methotrimeprazine or methotrimperazine or methozane or 
milezin or minozinan or neozine or neuractil or neurocil or nirvan or nozinan or "rp 7044" or rp7044 or 
sinogan or "skf 5116" or skf5116 or tiscerin or tisercin or veractil).mp. 
2 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or 
toddler* or paediatric* or pediatric*).mp. 
3 1 and 2 
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PsycINFO: Search strategy for OvidSP PsycINFO <1806 to March Week 1 2015> 
Set History 
1 Methotrimeprazine/ or ("apo-methoprazine" or "bayer 1213" or "cl 36467" or "cl 39743" or cl36467 or 
cl39743 or hirnamin or methoxyphenothiazine or "l mepromazine" or levium or "levo mepromazine " 
or "levo promazine" or levomeprazine or levomepromazine or levopromazin or levopromazine or 
levoprome or levozin or mepromazine or methotrimeprazine or methotrimperazine or methozane or 
milezin or minozinan or neozine or neuractil or neurocil or nirvan or nozinan or "rp 7044" or rp7044 or 
sinogan or "skf 5116" or skf5116 or tiscerin or tisercin or veractil).mp. 
2 limit 1 to (100 childhood <birth to age 12 yrs> or 120 neonatal <birth to age 1 mo> or 140 infancy <2 to 
23 mo> or 160 preschool age <age 2 to 5 yrs> or 180 school age <age 6 to 12 yrs> or 200 adolescence 
<age 13 to 17 yrs>) 
3 (infan* or neonat* or child* or adolescen* or teen* or girl* or boy* or youth* or tot or tots or 
toddler* or paediatric* or pediatric*).mp. 
4  1 and 3 
5 2 or 4 
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Supplementary Table IV:  Treatment of Breakthrough CINV – Summary of Included Studies 

First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Pediatric Studies 
No studies identified 
Adult Studies 
5HT-3 Antagonist - Granisetron 
Jones 
(2011) [1] 
 
 Prospective observational trial 
 Aim: Describe the response to 
antiemetic therapy taken for 
breakthrough CINV 
 N = 27 
 Adults with cancer receiving 
chemotherapy 
 Median age: 57 yrs; range: 30-72 
yrs 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Nausea and/or vomiting 
requiring antiemetic 
rescue medication 
occurring any time 
during the first 3 days 
post-chemotherapy 
Prophylactic regimen: 
Dexamethasone: 25/27 (93%) 
Granisetron: 20/27 (74%) 
Palonosetron: 7/27 (26%) 
Aprepitant: 1/27 (4%) 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine (authors report prophylactic regimens were based 
on antiemetic guidelines)
 
Breakthrough intervention: 
G1:  Prochlorperazine 10mg PO   
        (n=24) 
 
G2: 5-HT antagonist (granisetron 1mg PO (n=1), ondansetron 
8mg IV (n=1), ondansetron 8mg sublingually (n=1) 
Proportion with complete control of breakthrough vomiting: 
G1: 23/24 (96%) 
G2: 3/3 (100%)  
 
Proportion with complete control of breakthrough nausea: 
G1: 2/24 (8.3%) 
G2: 1/3 (33.3%) 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 3 days) 
 
Timeframe of assessments: Acute phase (baseline (when 
breakthrough treatment initiated) then every half hour x 4hrs) 
 
Marty 
(1990)[2] 
 
 Prospective trial 
 Aim: Compare the efficacy and 
safety of granisetron vs 
chlorpromazine + dexamethasone 
for CINV, evaluation of rescue with 
a second dose of granisetron was 
evaluated secondarily in the 
granisetron arm 
 N = 23 
 Adults with cancer receiving 
chemotherapy 
 Median age: Not reported for 
breakthrough cohort 
 CINV assessment: patient and 
clinician report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Moderate or severe 
nausea 
Prophylactic regimen: 
Granisetron 40mcg/kg IV (5 min pre-chemo) 
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Additional Granisetron doses of 40mcg/kg IV up to a 
maximum of 120mcg/kg  
 
Proportion with complete control of breakthrough CINV after 
1 additional granisetron dose: 11/23 (47.8%) 
 
Proportion with complete control of breakthrough CINV after 
2 additional granisetron doses: 4/8 (50%) 
 
Time of occurrence of breakthrough CINV: acute phase 
 
Timeframe of assessments: acute phase (30min after 
administration of additional granisetron doses) 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Riviere 
(1994)[3] 
 
 Prospective open-label study 
 Aim: Compare the efficacy and 
safety of 3 different doses of 
granisetron, evaluation of rescue 
with a second dose of granisetron 
was evaluated secondarily 
 N =  64 
 Adult patients receiving cisplatin-
containing chemotherapy 
 Median age: Not reported for 
breakthrough cohort  
 CINV assessment: patient and 
clinician report 
 Emetogenicity classification: highly 
emetogenic 
Moderate or severe 
nausea (more than mild 
nausea or vomiting 
occurred) 
Prophylactic regimen for all patients (5 min pre-chemo): 
G1: Granisetron 2mcg/kg IV 
G2: Granisetron 10mcg/kg IV 
G3: Granisetron 40mcg/kg IV 
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Granisetron 3mg IV up to 2 x’s, administered at least 10min 
apart 
 
Proportion with complete control of breakthrough CINV after 
1 additional granisetron dose: 
G1: 26/30 (86.7%) 
G2: 12/19 (63.2%) 
G3: 9/15 (60%) 
 
Proportion with complete control of breakthrough CINV after 
2 additional granisetron doses: 
G1: 5/12 (41.7%) 
G2: 9/11 (81.8%) 
G3: 2/7 (28.6%) 
 
Time of occurrence of breakthrough CINV: not reported 
 
Timeframe of assessments: acute phase (baseline, 6hrs, 
12hrs, 18hrs, and 24hrs)  
Takigawa 
(1996)[4] 
 
 Prospective observational trial 
 Aim: Determine the usefulness of 
granisetron rescue therapy for 
CINV 
 N = 20  
 Adults with urogenital malignant 
tumors receiving chemotherapy 
(including cisplatin) 
 Mean age: 61.9 ± 15 yrs; range: 25-
76 yrs 
 CINV assessment: Not reported, 
patients examined by a healthcare 
professional q6h for 24hrs 
 Emetogenicity classification: highly 
emetogenic 
No response to 
antiemetics or emesis 
Prophylactic regimen: 
Not reported 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Breakthrough intervention: 
Granisetron 3mg IV administered 30min after the onset of 
nausea or vomiting 
Proportion with complete control of breakthrough vomiting: 
5/20 (25%) 
 
Proportion with complete control of breakthrough nausea: 
15/20 (75%) 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: not reported 
 
Timeframe of assessments: acute phase (q6h x 24hrs) 
5HT-3 Antagonist - Ondansetron 
Ariyoshi 
(1992)[5] 
 
 Double-blind randomized 
comparison with placebo 
 Aim: Determine the antiemetic 
efficacy and safety of ondansetron 
tablets  
 N = 12  
 Adults with cancer receiving a 
single dose of cisplatin 50mg/m
2
 or 
higher 
 Median Age: Not reported for 
breakthrough cohort  
 CINV assessment: Not reported, 
patients examined by a healthcare 
professional q6h for 24hrs 
 Emetogenicity classification: highly 
emetogenic 
“Satisfactory” anti-
emetic effects not 
obtained  
Prophylactic regimen: 
Ondansetron 4mg PO once (2hrs pre-chemo)  
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Ondansetron 4mg IV once 
Proportion with complete control of breakthrough vomiting: 
not reported 
 
Proportion with complete control of breakthrough nausea: 
not reported 
 
Proportion with complete  control of breakthrough CINV: not 
reported, 5/12 (41.7%) achieved a “satisfactory response” 
 
Timeframe of assessments: acute phase (q6h x 24hrs after 
administration of cisplatin) 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Fabi 
(2008)[6] 
 
 Open-label randomized trial 
 Aim: evaluate the efficacy and 
safety of two different schedules of 
ondansetron as rescue antiemetic 
treatment  
 N = 44 
 Adults with cancer receiving 
chemotherapy 
 Median age: Not reported for 
breakthrough cohorts 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately emetogenic 
At least 1 episode of 
nausea and/or vomiting 
occurring from days 2-6 
of cycle 1 of 
chemotherapy 
Prophylactic regimen for all patients: 
Day 1: Dexamethasone 8mg IV + ondansetron 8mg IV  
Days 2-5: Dexamethasone 8mg PO once daily 
 
*Guideline consistent antiemetic prophylaxis: yes 
 
Breakthrough intervention: 
G1:  Ondansetron 8mg IM (n=22) 
G2:  ODT ondansetron 16mg PO (n=22) 
 
Proportion with complete control of breakthrough vomiting: 
G1: 7/22 (31.8%) 
G2: 18/22 (81.8%) p=0.001 
 
Proportion with complete control of breakthrough nausea: 
G1: 9/22 (40.9%) 
G2: 17/22 (77.3%) p=0.01 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: delayed phase 
(days 2-6) 
 
Timeframe of assessments: acute and delayed phases 
(patients followed for 6 days following chemo) 
Jones 
(2011)[1] 
 
 Prospective observational trial 
 Aim: Describe the response to 
antiemetic therapy taken for 
breakthrough CINV 
 N = 27 
 Adults with cancer receiving 
chemotherapy 
 Median age: 57 yrs; range: 30-72 
yrs 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Nausea and/or vomiting 
requiring antiemetic 
rescue medication 
occurring any time 
during the first 3 days 
post-chemotherapy 
Prophylactic regimen: 
Dexamethasone: 25/27 (93%) 
Granisetron: 20/27 (74%) 
Palonosetron: 7/27 (26%) 
Aprepitant: 1/27 (4%) 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine (authors report prophylactic regimens were based 
on antiemetic guidelines)
 
Breakthrough intervention: 
G1:  Prochlorperazine 10mg PO   
        (n=24) 
 
G2: 5-HT antagonist (granisetron 1mg PO (n=1), ondansetron 
8mg IV (n=1), ondansetron 8mg sublingually (n=1) 
Proportion with complete control of breakthrough vomiting: 
G1: 23/24 (96%) 
G2: 3/3 (100%)  
 
Proportion with complete control of breakthrough nausea: 
G1: 2/24 (8.3%) 
G2: 1/3 (33.3%) 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 3 days) 
 
Timeframe of assessments: Acute phase (baseline (when 
breakthrough treatment initiated) then every half hour x 4hrs) 
 
 
 
 
Ohta 
(1992)[7] 
 
 Double-blind randomized 
comparison with placebo 
 Aim: Determine the antiemetic 
efficacy and safety of IV 
ondansetron  
 N = 7  
 Adults with cancer receiving a 
single dose of cisplatin 50mg/m
2
 or 
higher 
 Median age: Not reported for 
breakthrough cohort 
 CINV assessment: Not reported, 
patients examined by a healthcare 
professional q6h for 24hrs 
 Emetogenicity classification: highly 
emetogenic 
Insufficient anti-emetic 
effect after initial dose 
of IV ondansetron 
Prophylactic regimen: 
Ondansetron 4mg IV (15 min pre-chemo) 
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Ondansetron 4mg IV once 
 
Proportion with complete control of breakthrough vomiting: 
not reported 
 
Proportion with complete control of breakthrough nausea: 
not reported 
 
Proportion with complete  control of breakthrough CINV: not 
reported, 1/7 (14.3%) achieved an “inhibitory effect” from the 
rescue ondansetron dose 
 
Timeframe of assessments: acute phase (q6h for the first 
24hrs after administration of cisplatin) 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
5HT-3 Antagonist -   Palonosetron 
Musso 
(2009)[8] 
 
 Prospective observational trial 
 Aim: Evaluate the efficacy of a 
single dose of palonosetron for 
CINV control, evaluation of rescue 
with a second dose of palonosetron 
was evaluated secondarily 
 N =27  
 Adolescents and adults with 
haematological malignancies 
receiving multiple day 
chemotherapy (2-7 days) 
 Median age: Not reported for 
breakthrough cohorts 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Not reported Prophylactic regimen: 
G1: Dexamethasone 8mg IV + palonosetron 0.25mg IV on day 
1 (15 min pre-chemo) 
Dexamethasone 4mg IV twice daily was administered every 
day during the entire chemotherapy period 
 
G2: Dexamethasone 8mg IV + ondansetron 8mg IV on day 1 
(15 min pre-chemo) 
Dexamethasone 4mg IV twice daily was administered every 
day during the entire chemotherapy period 
 
Dexamethasone excluded for patients receiving DHAP 
(dexamethasone + cisplatin + cytarabine) 
 
*Guideline consistent antiemetic prophylaxis: yes for MEC, no 
for HEC 
 
Breakthrough intervention: 
G1: Palonosetron 0.25mg IV 72 hrs after administration of 
the first dose 
 
G2: Metoclopramide 20mg IV q6h or q12h  
Proportion with complete control of breakthrough vomiting: 
not reported 
 
Proportion with complete control of breakthrough nausea: 
not reported 
 
Proportion with complete control of breakthrough CINV: 
G1: 6/9 (67%) 
G2: 4/18 (22%) p=0.039 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 5 days) 
 
Timeframe of assessments: not reported 
 
Musso 
(2010)[9] 
 
 Prospective open-label trial 
 Aim: Evaluate the efficacy of a 
single dose of palonosetron for 
CINV control, evaluation of rescue 
with a second dose of palonosetron 
was evaluated secondarily 
 N = 51  
 Adolescents and adults with 
haematological malignancies 
receiving conditioning for 
autologous stem cell transplant 
 Median age: Not reported for 
breakthrough cohorts 
 CINV assessment: patient reported 
 Emetogenicity classification: 
moderately or highly emetogenic 
 
Not reported Prophylactic regimen for all patients: 
Dexamethasone 8mg IV + palonosetron 0.25mg IV on day 1 
(30 min pre-chemo) 
Dexamethasone 4mg IV twice daily was administered every 
other day for the remainder of the conditioning regimen 
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Palonosetron 0.25mg IV 48 or 72 hrs after administration of 
the first dose 
 
Proportion with complete control of breakthrough vomiting 
when palonosetron administered 72hrs after initial dose: 
25/51 (50%) 
 
Proportion with complete control of breakthrough vomiting 
when palonosetron administered 48hrs after initial dose: 9/20 
(45%)  
 
Proportion with complete control of breakthrough nausea: 
Not reported 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough AINV: delayed phase 
 
Timeframe of assessments: not reported 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Methotrimeprazine 
McCabe 
(2003)[10] 
 
 Prospective observational study 
 Aim: Evaluate the efficacy of 
levomepromazine for management 
of breakthrough CINV 
 N = 32 
 Adult patients with high grade 
delayed chemotherapy-induced 
emesis requiring hospital admission 
to control this 
 Median age: 58 yrs; range: 35-76 
yrs 
 CINV assessment: patient report 
 Emetogenicity classification: highly 
emetogenic 
 
Delayed chemotherapy-
induced emesis Grade II 
and above (graded using 
the NCI-CTC)  
Prophylactic regimen for all patients: various potential 
regimens described (not reported which regimens actually 
received by patients included in the analysis) 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Breakthrough intervention: 
Levomepromazine 25mg SC over 24-48 hrs 
Proportion with complete control of breakthrough vomiting in 
24 hours: 28/32 (88%) 
 
Proportion with complete control of breakthrough vomiting in 
48 hours: 30/32 (94%) 
 
Proportion with complete control of breakthrough nausea in 
24 hours: 24/32 (75%) 
 
Proportion with complete control of breakthrough nausea in 
48 hours: 30/32 (94%) 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phase (within 24 and 48 hours) 
 
Timeframe of assessments: acute and delayed phases 
(baseline, 24hrs , and 48hrs) 
 
 
Metoclopramide 
Musso 
(2009)[8] 
 
 Prospective observational trial 
 Aim: Evaluate the efficacy of a 
single dose of palonosetron for 
CINV control, evaluation of rescue 
with a second dose of palonosetron 
was evaluated secondarily 
 N =27  
 Adolescents and adults with 
haematological malignancies 
receiving multiple day 
chemotherapy (2-7 days) 
 Median age: Not reported for 
breakthrough cohorts 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Not reported Prophylactic regimen: 
G1: Dexamethasone 8mg IV + palonosetron 0.25mg IV on day 
1 (15 min pre-chemo) 
Dexamethasone 4mg IV twice daily was administered every 
day during the entire chemotherapy period 
 
G2: Dexamethasone 8mg IV + ondansetron 8mg IV on day 1 
(15 min pre-chemo) 
Dexamethasone 4mg IV twice daily was administered every 
day during the entire chemotherapy period 
 
Dexamethasone excluded for patients receiving DHAP 
(dexamethasone + cisplatin + cytarabine) 
 
*Guideline consistent antiemetic prophylaxis: yes for MEC, no 
for HEC 
 
Breakthrough intervention: 
G1: Palonosetron 0.25mg IV 72 hrs after administration of 
the first dose 
 
G2: Metoclopramide 20mg IV q6h or q12h  
 
Proportion with complete control of breakthrough vomiting: 
not reported 
 
Proportion with complete control of breakthrough nausea: 
not reported 
 
Proportion with complete control of breakthrough CINV: 
G1: 6/9 (67%) 
G2: 4/18 (22%) p=0.039 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 5 days) 
 
Timeframe of assessments: not reported 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Navari 
(2013)[11] 
 
 Double-blinded randomized trial 
 Aim: Compare the use of 
olanzapine vs metoclopramide for 
the treatment of breakthrough 
CINV 
 N = 108 
 Chemotherapy-naïve adults with 
cancer receiving chemotherapy 
(cisplatin ≥ 70mg/m
2
 or doxorubicin 
≥ 50mg/m
2
 +  cyclophosphamide ≥ 
600mg/m
2
) 
 Median age: 
G1: 61 yrs; range: 38-75 yrs 
G2: 63 yrs; range: 42-79 yrs 
 CINV assessment: patient report 
 Emetogenicity classification: highly 
emetogenic 
Any emesis and/or any 
moderate to severe 
nausea  (>3 on visual 
analogue scale of 0 to 
10) 
Prophylactic regimen for all patients (30-60min pre-chemo): 
Day 1: Dexamethasone 12mg IV + palonosetron 0.25mg IV + 
fosaprepitant 150mg IV 
Days 2-4: Dexamethasone 4mg PO twice daily 
 
*Guideline consistent antiemetic prophylaxis: yes 
 
Breakthrough intervention: 
G1:  Olanzapine 10mg PO once daily x 3      
        days (n=56) 
 
G2:  Metoclopramide 10mg PO q8h x 3 days (n=52) 
 
Oral dexamethasone discontinued immediately once 
breakthrough treatment with olanzapine initiated 
 
Proportion with complete control of breakthrough vomiting: 
G1: 39/56 (70%) 
G2: 16/52 (31%) p<0.01 
 
Proportion with complete control of breakthrough nausea: 
G1: 38/56 (68%) 
G2: 12/52 (23%) p<0.01 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 3 days) 
 
Timeframe of assessments: acute and delayed phases (at least 
once daily x 72hrs) 
Olanzapine 
Chanthawong 
(2014)[12]  
 
 Phase II open label pilot study 
 Aim: Evaluate the efficacy and 
safety  of olanzapine for 
breakthrough CINV  
 N = 46 
 Adults with cancer receiving 
chemotherapy 
 Median age: 33.5 yrs (males; 18 yrs 
(females) 
 Emetogenicity classification: highly 
emetogenic 
Any vomiting episode 
during days 1 to 4 
Prophylactic regimen for all patients: 
Day 1: Ondansetron 24mg IV BID + dexamethasone 10mg IV 
BID 
Days 2-4: Metoclopramide 10mg TID PO + dexamethasone 
10mg BID PO 
 
*Guideline consistent antiemetic prophylaxis: no 
 
Breakthrough intervention: 
Olanzapine 5 mg PO q12h x 2 doses 
Lorazepam 0.5 to 2mg/dose PO q4 – 6h PRN added if 
olanzapine not effective   
 
Proportion with complete control of breakthrough vomiting: 
28/46 (60.8%) 
 
Proportion with complete control of breakthrough nausea: 
23/46 (50.0%) 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV:  not reported 
 
Timeframe of assessments: q6h x 24 hrs after receipt of 
olanzapine 
Navari 
(2013)[11] 
 
 Double-blinded randomized trial 
 Aim: Compare the use of 
olanzapine vs metoclopramide for 
the treatment of breakthrough 
CINV 
 N = 108 
 Chemotherapy-naïve adults with 
cancer receiving chemotherapy 
(cisplatin ≥ 70mg/m
2
 or doxorubicin 
≥ 50mg/m
2
 +  cyclophosphamide ≥ 
600mg/m
2
) 
 Median age: 
G1: 61 yrs; range: 38-75 yrs 
G2: 63 yrs; range: 42-79 yrs 
 CINV assessment: patient report 
 Emetogenicity classification: highly 
emetogenic 
 
 
 
Any emesis and/or any 
moderate to severe 
nausea  (>3 on visual 
analogue scale of 0 to 
10) 
Prophylactic regimen for all patients (30-60min pre-chemo): 
Day 1: Dexamethasone 12mg IV + palonosetron 0.25mg IV + 
fosaprepitant 150mg IV 
Days 2-4: Dexamethasone 4mg PO twice daily 
 
*Guideline consistent antiemetic prophylaxis: yes 
 
Breakthrough intervention: 
G1:  Olanzapine 10mg PO once daily x 3      
        days (n=56) 
 
G2:  Metoclopramide 10mg PO q8h x 3 days (n=52) 
 
Oral dexamethasone discontinued immediately once 
breakthrough treatment with olanzapine initiated 
 
Proportion with complete control of breakthrough vomiting: 
G1: 39/56 (70%) 
G2: 16/52 (31%) p<0.01 
 
Proportion with complete control of breakthrough nausea: 
G1: 38/56 (68%) 
G2: 12/52 (23%) p<0.01 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 3 days) 
 
Timeframe of assessments: acute and delayed phases (at least 
once daily x 72hrs) 
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First Author 
(Year) 
Study Design, Objective and 
Population 
Definition of 
Breakthrough CINV 
Antiemetic Prophylaxis and Interventions 
Proportion with Complete Control of Breakthrough 
Nausea and/or Vomiting 
Prochlorperazine 
Jones 
(2011)[1] 
 
 Prospective observational trial 
 Aim: Describe the response to 
antiemetic therapy taken for 
breakthrough CINV 
 N = 27 
 Adults with cancer receiving 
chemotherapy 
 Median age: 57 yrs; range: 30-72 
yrs 
 CINV assessment: patient report 
 Emetogenicity classification: 
moderately or highly emetogenic 
Nausea and/or vomiting 
requiring antiemetic 
rescue medication 
occurring any time 
during the first 3 days 
post-chemotherapy 
Prophylactic regimen: 
Dexamethasone: 25/27 (93%) 
Granisetron: 20/27 (74%) 
Palonosetron: 7/27 (26%) 
Aprepitant: 1/27 (4%) 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine (authors report prophylactic regimens were based 
on antiemetic guidelines) 
 
Breakthrough intervention: 
G1:  Prochlorperazine 10mg PO   
        (n=24) 
 
G2: 5-HT antagonist (granisetron 1mg PO (n=1), ondansetron 
8mg IV (n=1), ondansetron 8mg sublingually (n=1) 
 
Proportion with complete control of breakthrough vomiting: 
G1: 23/24 (96%) 
G2: 3/3 (100%)  
 
Proportion with complete control of breakthrough nausea: 
G1: 2/24 (8.3%) 
G2: 1/3 (33.3%) 
 
Proportion with complete control of breakthrough CINV: not 
reported 
 
Time of occurrence of breakthrough CINV: acute and delayed 
phases (over 3 days) 
 
Timeframe of assessments: Acute phase (baseline (when 
breakthrough treatment initiated) then every half hour x 4hrs) 
Other 
Bleicher 
(2008)[13] 
 
 2 prospective open-label trials 
 Aim: Describe the efficacy of ABH 
gel in reducing breakthrough CINV 
 N =33 
 Adults with cancer receiving 
chemotherapy 
 Median age: Not reported 
 CINV assessment: patient report 
 Emetogenicity classification: highly 
emetogenic 
Significant nausea 
and/or vomiting in the 
days following 
chemotherapy 
Prophylactic regimen for all patients: not reported 
 
*Guideline consistent antiemetic prophylaxis: unable to 
determine (authors report patients were given standard 
antiemetic prophylaxis similar to those recommended in 
established guidelines with ASCO guidelines referenced) 
 
Breakthrough intervention: 
0.5mL of ABH gel applied topically to the wrists q6h prn 
ABH 0.5 mL contains: lorazepam 2 mg,  
diphenhydramine 25 mg, haloperidol 2mg 
ABH gel ingredients: 120mg lorazepam, 1500mg 
diphenhydramine, 120mg haloperidol, 12mL lecithin 
organogel, 5mL ethoxydiglycol, 1mL water, and 60mL 
pluronic gel 20% qs 
Proportion with complete control of breakthrough vomiting: 
not reported 
 
Proportion with complete control of breakthrough nausea: 
not reported 
 
Proportion with complete control of breakthrough CINV: 
10/33 (30.3%) 
 
Time of occurrence of breakthrough CINV: not reported 
 
Timeframe of assessments: variable (within 1 month for 23 
patients; at baseline and every half hour x 4hrs in 10 patients) 
Emetogenicity classified according to the MASCC and ASCO guidelines 
*Prophylaxis considered “guideline consistent” based on current recommendations provided by MASCC and/or ASCO and/or NCCN 
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Supplementary Table V:  Adverse Effects Reported in Pediatric Studies Evaluating the Use of Methotrimeprazine (Levopromazine) – Summary of Included 
Studies 
 
Author Study Aim Patient 
Characteristics 
Methotrimeprazine Dose Length of 
Treatment 
Adverse 
Effects 
Monitored 
Adverse 
Effects 
Reported 
Comments 
Randomized or Non-Randomized Trials 
None 
 
Retrospective Reviews, Case Series and Case Reports 
Hohl 
(2013)[14] 
 
Retrospective review of 
methotrimeprazine use for 
palliative symptoms in 
children and infants 
N=18  
Age: 16 days-17 
yrs (age at 
death) 
M:F = NR 
 
Range: 0.02 to 0.5 mg/kg/dose 
q4h (n=6), q6h (n=6), q8h 
(n=1), q24h (n=4) regularly or 
PRN: q30min (n=3), q1h (n=4), 
q4h (n=4), q6h (n=2) 
 
IV (n=13), PO/GT (n=6), SC 
(n=4) 
NR NR EPS: 0/18 
NMS:0/18 
Sedation: 6/18 
Most patients received concurrent 
medications which may cause EPS. 
However EPS not reported as an adverse 
effect experienced by any patient. 
Snoek 
(2014)[15] 
 
Retrospective review of 
methotrimeprazine use for 
difficult sedation in 
pediatric ICU  
N=7 
Age: 1 -17 yrs  
M:F = NR 
 
Range: 0.5 – 1.9 mg/kg/dose 
given q8h enterally  
 
Varied; 
Range:  
16–149 hrs 
NR EPS: 0/7 
Fever: 2/7 
 
All patients received concurrent 
medications, some of which may cause 
EPS. Fever developed in 1 child with 
pneumonia and methotrimeprazine was 
discontinued.  A second child developed 
fever which resolved despite continuation 
of methotrimeprazine. 
 
van der 
Zwann 
(2012)[16]  
Case series of 4 pediatric 
patients given 
methotrimeprazine for 
treatment of refractory 
agitation  
N=4  
Age (mean): 8.4 
yrs    
        (range): 0.7-
15 yrs 
M:F = 3:1 
1 mg TID or QID IV, 
10 mg bid enterally, 
6.25 mg bid orally 
 
 
NR NR No adverse 
effects 
reported 
All patients received concurrent 
medications which may cause EPS. 
However EPS not reported as an adverse 
effect experienced by any patient 
Eshel 
(1994)[17] 
 
Case report of 
methotrimeprazine 
treatment and respiratory 
distress in a child 
N=1  
Age: 11 yrs 
Male 
 
125 mg PO daily NR (at least 
3 weeks) 
NR dyspnea 
lethargy, 
hypothermia, 
bradycardia 
and prolonged 
QTc 
No additional concomitant medications 
were administered. 
Methotrimeprazine was discontinued, 
supportive care initiated. ECG at 5 weeks 
revealed normal sinus rhythm and QTc 
ECG: electrocardiogram; EPS: extrapyramidal symptoms; NMS: neuroleptic malignant syndrome; NR: not reported; PRN: as needed; QTc= corrected QT interval 
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Supplementary Table VI:  Prevention of CINV in Patients with Refractory CINV – Summary of Included Studies 
 
First 
Author 
(Year) 
Study Design, Objective and 
Population 
Definition of Refractory CINV and CINV Prophylaxis 
Provided During Previous Chemo Blocks 
Antiemetic Interventions 
Proportion with Complete Control of 
Refractory Nausea and/or Vomiting 
Pediatric Studies 
5HT-3 Antagonist – Tropisetron  
Hachimi-
Idrissi 
(1993)[18] 
 
 Prospective open-label trial 
 Aim: Determine the efficacy 
and tolerability of ICS 205-930 
(tropisetron) in children with 
refractory CINV  
 N = 19 (169 chemotherapy 
courses) 
 Children with cancer receiving 
chemotherapy  over 1-5 days 
 Median age: 9 yrs; range: 2-
16yrs 
 CINV assessment:  parent 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Grade 3 emesis (> 4 episodes of vomiting/day) 
 
Previous prophylactic regimen: 
Alizapride 4-6mg/kg/day or metoclopramide 5mg/kg day 
 
Guideline consistent antiemetic prophylaxis: no 
 
Tropisetron 0.2mg/kg IV (max 5mg) once 
daily on each day prior to chemo and then 
PO for 5 days after chemo if patients 
received cisplatin 
Proportion of courses with complete control of 
vomiting: 131/169 (77.5%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: not reported 
Aprepitant 
Bauters 
(2013)[19] 
 
 Retrospective, observational 
study  
 Aim: Determine the efficacy of 
aprepitant in children and 
adolescents with refractory 
CINV 
 N = 20 (104 chemotherapy 
cycles) 
 Children with cancer receiving 
chemotherapy 
 Mean age: 14 yrs; range: 8-
16yrs 
 CINV assessment:  Only 
vomiting evaluated 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
 
Intolerable and uncontrollable emesis in the preceding 
chemo cycle 
 
Previous prophylactic regimen: 
Tropisetron 0.2mg/kg IV once daily (max 5mg) or ondansetron 
5-8mg/m
2
 bid (max 8mg/dose) or granisetron 0.04mg/kg once 
daily (max 9mg) + dexamethasone 3mg/m
2
 once-twice daily  
given at least 30 minutes prior to chemo 
 
Guideline consistent antiemetic prophylaxis: yes (no for 
patients receiving HEC > 12yrs where aprepitant use 
permitted) 
 
Day 1: Aprepitant 125mg PO once 
Days 2-3: Aprepitant 80mg po  once daily 
Plus Tropisetron 0.2mg/kg IV once daily 
(max 5mg) or ondansetron 5-8mg/m
2
 bid 
(max 8mg/dose) or granisetron 0.04mg/kg 
once daily (max 9mg) + dexamethasone 
1.5mg/m
2
 once-twice daily  given at least 30 
minutes prior to chemo 
 
Proportion with complete control of vomiting:  
   patients: 10/20 (50%) 
   courses: 89/104 (85.6%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: not reported 
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First 
Author 
(Year) 
Study Design, Objective and 
Population 
Definition of Refractory CINV and CINV Prophylaxis 
Provided During Previous Chemo Blocks 
Antiemetic Interventions 
Proportion with Complete Control of 
Refractory Nausea and/or Vomiting 
Adult Studies 
5HT-3 Antagonists – Granisetron 
Arevalo-
Araujo 
(2013)[20] 
 [abstract] 
 Prospective trial (abstract) 
 Aim: Determine the antiemetic 
efficacy of APF530 (sustained 
formulation of granisetron) in 
refractory patients  
 N = 72 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported 
 CINV assessment: not reported 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Failure to achieve a complete response (no emesis or rescue 
medication) with palonosetron during cycle 1 
 
Previous Prophylactic regimen: 
Palonosetron 0.25mg IV 
 
Guideline consistent antiemetic prophylaxis: no 
 
APF530 (sustained formulation of 
granisetron) 500mg SC 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete CINV response 
(defined as no emesis or rescue medications): 
   acute phase:  
      MEC: 11/19 (57.9%) 
      HEC: 7/12 (58.3%) 
   delayed phase:  
      MEC: 13/34 (38.2%) 
      HEC: 15/33 (45.5%) 
 
Timeframe of assessments: not 
reported/unable to determine 
Carmichael 
(1998)[21]  
 
 Prospective open-label trial 
 Aim: evaluate the tolerability 
and antiemetic efficacy of 
granisetron in refractory 
patients 
 N = 456 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report and direct observation 
for a minimum of 2hrs from the 
onset of chemotherapy 
administration 
 Emetogenicity classification: 
unable to determine/not 
reported 
Failed antiemetic therapy during the previous cycle 
 
Previous prophylactic regimens: 
One or more of the following: metoclopramide,  
Dexamethasone, alizapride, ondansetron, chlorpromazine, 
“other” 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Granisetron 3mg IV once 5min prior to 
chemo + up to 2 additional doses of 
granisetron 3mg IV with at least 10min 
between doses 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Overall proportion with complete CINV 
response (defined as no vomiting, mild or 
absent nausea, and no rescue medications): 
237/456 (52%) 
 
Timeframe of assessments: acute phase (first 
24hrs following chemo) 
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Author 
(Year) 
Study Design, Objective and 
Population 
Definition of Refractory CINV and CINV Prophylaxis 
Provided During Previous Chemo Blocks 
Antiemetic Interventions 
Proportion with Complete Control of 
Refractory Nausea and/or Vomiting 
De Wit 
(2001)[22] 
 
 Randomized, double-blind trial 
 Aim: evaluate the efficacy of 
crossing over to granisetron 
after CINV failure while 
receiving ondansetron 
 N = 40 
 Adults with cancer receiving 
cisplatin-or cyclophosphamide-
based chemotherapy 
 Median age:  
G1: 46yrs; range: 29-71yrs 
G2: 46yrs; range: 30-73yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
highly emetogenic 
≥ 2 vomits and/or severe nausea (no significant intake 
possible) or nausea lasting > 4hrs 
 
Previous prophylactic regimen: 
Day 1: Ondansetron 8mg IV + dexamethasone 10mg IV 
 
Guideline consistent antiemetic prophylaxis: no 
 
G1:  Granisetron 3mg IV + dexamethasone 
10mg IV (n=19) 
G2:  Ondansetron 8mg IV + dexamethasone 
10mg IV (n=21) 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete CINV protection 
(defined as no vomiting and no or mild 
nausea): 
G1: 9/19 (47.4%) 
G2: 1/21 (4.8%) p=0.005 
 
Timeframe of assessments: acute phase (first 
24hrs following chemo) 
Sigsgaard 
(2000)[23] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
efficacy of granisetron + 
prednisolone + metopimazine 
in refractory patients  
 N = 25  
 Adults with breast cancer 
receiving cyclophosphamide + 
fluorouracil + either 
methotrexate or epirubicin 
 Median age: 45yrs; range: 29-
66yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately emetogenic 
≥ 5 emetic episodes during any of days 1-5 following chemo 
or patients not satisfied with the antiemetic treatment during 
a previous chemotherapy cycle 
 
Previous prophylactic regimen: 
Either granisetron 3mg IV once OR prednisolone 25mg PO 
once a day x 3 days + metopimazine 30mg PO qid x 3 days 
 
Guideline consistent antiemetic prophylaxis: no 
 
Granisetron 3mg IV once + prednisolone 
25mg PO once a day x 3 days + 
metopimazine 30mg PO qid x 3 days 
 
Proportion of cycles with complete control of 
vomiting: 
   acute phase: 100/113 (88.5%) 
   delayed phase: 107/113 (94.7%) 
 
Proportion of cycles with complete control of 
nausea:  
   acute phase: 49/113 (43.4%) 
   delayed phase: 56/113 (49.6%) 
 
Proportion of cycles with complete control of 
CINV (defined as no emetic episodes (including 
vomits and retches)  and no or mild nausea): 
   acute phase: 85/113 (75.2%) 
   delayed phase: 93/113 (82.3%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
 
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5HT-3 Antagonists – Ondansetron 
Campora 
(1991)[24] 
 
 Prospective open-label trial 
 Aim: Evaluate the efficacy of 
ondansetron  for antiemetic 
prophylaxis in refractory 
patients  
 N = 24 
 Adults with cancer receiving 
chemotherapy 
 Median age: 53yrs; range: 21-
70yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
> 15 emetic episodes within 24hrs of therapy while receiving 
combination antiemetics 
 
Previous prophylactic regimen: 
Metoclopramide 0.5-1mg/kg IV + methylprednisolone 40-
125mg IV prior to chemo and repeated after 2hrs: 24/24 pts 
Lorazepam 2mg IV prior to chemo: 7/24 pts 
 
Guideline consistent antiemetic prophylaxis: no 
 
Ondansetron 8mg PO prior to chemo and 
repeated after 6 and 12hrs on day 1, then 
8mg PO tid on days 2-5 
Proportion with complete control of vomiting: 
   acute phase (day 1): 10/24  
      (41.7%) 
   day 2: 20/24 (83.3%%) 
   delayed phase (days 3-5):  
      24/24 (100%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
De Wit 
(2001) [22] 
 
 Randomized, double-blind trial 
 Aim: evaluate the efficacy of 
crossing over to granisetron 
after CINV failure while 
receiving ondansetron 
 N = 40 
 Adults with cancer receiving 
cisplatin-or cyclophosphamide-
based chemotherapy 
 Median age:  
G1: 46yrs; range: 29-71yrs 
G2: 46yrs; range: 30-73yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
highly emetogenic 
≥ 2 vomits and/or severe nausea (no significant intake 
possible) or nausea lasting > 4hrs 
 
Previous prophylactic regimen: 
Day 1: Ondansetron 8mg IV + dexamethasone 10mg IV 
 
Guideline consistent antiemetic prophylaxis: no 
 
G1:  Granisetron 3mg IV + dexamethasone 
10mg IV (n=19) 
G2:  Ondansetron 8mg IV + dexamethasone 
10mg IV (n=21) 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete CINV protection 
(defined as no vomiting and no or mild 
nausea): 
G1: 9/19 (47.4%) 
G2: 1/21 (4.8%) p=0.005 
 
Timeframe of assessments: acute phase (first 
24hrs following chemo) 
Du Bois 
(1990)[25] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
efficacy of ondansetron  
 N = 17 (34 chemotherapy 
cycles) 
 Adults with cancer receiving 
platinum based chemotherapy 
 Median age: 63.5yrs; range 41-
75yrs 
 CINV assessment: Patient 
report 
 Emetogenicity classification: 
highly emetogenic 
Severe emesis refractory to standard antiemetic regimen 
 
Previous prophylactic regimen: 
Metoclopramide (2-3mg/kg) ± additional antiemetics 
 
Guideline consistent antiemetic prophylaxis: no 
 
Day 1: Ondansetron 8mg IV 30 min prior to 
chemo, then 1mg/hr as a continuous 
infusion over 8-24hrs 
Day 2-5: Ondansetron 8mg PO TID 1hr 
before food 
Proportion of cycles with complete control of 
vomiting: 7/34 (20.6%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 8 days) 
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Harvey  
(1991)[26] 
 
 Prospective open-label trial 
 Aim: Report on experience with 
ondansetron  for antiemetic 
prophylaxis in refractory 
patients 
 N = 25 
 Adults with ovarian cancer or 
testicular germ cell tumors 
receiving carboplatin + 
etoposide 
 Median age: 52yrs; range: 24-
68yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
highly emetogenic 
Multiple episodes of vomiting (≥ 3) during the first 24hrs of 
the previous course of chemo 
 
Previous prophylactic regimens: 
Metoclopramide 2mg/kg q2h x 3-5 doses: 22 pts 
Metoclopramide 0.5mg-1/kg IV q2h x 4 doses: 3 pts 
Lorazepam 1-2mg PO pre-chemo: 16 pts 
Dexamethasone 8mg IV q6h x 2 doses: 13 pts 
Haloperidol 2.5mg IV q4h prn: 8 pts 
Scopaderm patch: 15 pts 
 
Guideline consistent antiemetic prophylaxis: no 
 
Ondansetron 4mg IV and 4mg PO prior to 
chemo, then 8mg PO 6 and 12hrs later, and  
8mg PO tid for an additional 4 days 
Proportion with complete control of vomiting: 
   acute phase: 17/25 (68%) 
   delayed phase: 14/25 (56%) 
 
Proportion with complete control of nausea 
   acute phase: 14/25 (56%) 
   delayed phase: 12/25 (48%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Mitchell  
(1992)[27] 
 
 Prospective open-label trial 
 Aim: Report on experience with 
ondansetron in refractory 
patients  
 N = 91 
 Adults with cancer receiving 
chemotherapy 
 Median age: 
G1 (non-cisplatin 
chemotherapy): 47 yrs; range: 
19-72yrs  
G2 (cisplatin-based 
chemotherapy): 33yrs; range: 
18-44yrs  
 CINV assessment: patient 
report (daily) and nurse report 
(first 24hrs) 
 Emetogenicity classification: 
minimal, low, moderate and 
highly emetogenic agents 
At least 3 (non-cisplatin chemo) or 5 (cisplatin-based chemo) 
episodes of vomiting in the first 24hrs following previous 
chemo 
 
Previous prophylactic regimen: 
G1: Metoclopramide <0.5mg/kg IV/PO x 1-6 doses: 35 pts 
Metoclopramide 0.5mg-2/kg IV x 1-5 doses: 30 pts 
Lorazepam 1-5mg PO: proportion of pts not reported 
Dexamethasone 8mg IV q6h x 2-4 doses: proportion of pts not 
reported 
Hyoscine transdermal patch: proportion of pts not reported 
G2: Metoclopramide 1-2mg/kg IV x 3-5 doses: proportion of 
pts not reported  
Lorazepam: proportion of pts not reported 
Dexamethasone: proportion of pts not reported 
Haloperidol: proportion of pts not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
G1: Ondansetron 4mg IV and 4mg PO prior 
to chemo, then 8mg PO after 6 and 12hrs, 
then 8mg PO q8h on days 2-5 (n=75) 
G2: Ondansetron 8mg IV prior to chemo, 
then 1mg/hr infusion for 8hrs and 8mg PO at 
the end of the infusion,  then 8mg PO q8h 
on days 2-6 (n=16) 
Proportion with complete control of vomiting: 
   acute phase: 
      G1: 52/75 (69%) 
      G2: 0/16 (0%) 
   delayed phase: 
      G1: 45/75 (60%) 
      G2: 1/16 (6.3%) 
 
Proportion with complete control of nausea: 
   acute phase: 
      G1: 38/75 (51%) 
      G2: 2/16 (12.5%) 
   delayed phase: 
      G1: 27/75 (36%) 
      G2: 3/16 (18.8%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5-6 days) 
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Seynaeve 
(1991)[28] 
 
 Prospective open-label trial 
 Aim: Evaluate the efficacy of 2 
dosage regimens of 
ondansetron for antiemetic 
prophylaxis in refractory 
patients  
 N = 35 
 Adults with cancer receiving 
chemotherapy 
 Median age:  
G1: 45yrs; range: 20-66yrs 
G2: 3yrs; range: 37-72yrs 
(Note: median age likely 
publication error based on the 
range reported by the authors) 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
> 5 emetic episodes while receiving previous standard 
antiemetics 
 
Previous prophylactic regimen: 
Alizapride or metoclopramide 5-6mg/kg/day 
 
Guideline consistent antiemetic prophylaxis: no 
 
G1: Ondansetron 4mg IV and 4mg PO prior 
to chemo, then 4mg PO qid for an additional 
4 days (n=19) 
G2: Ondansetron 8mg IV prior to chemo, 
then 8mg PO tid for an additional 4 days 
(n=16) 
Proportion with complete control of vomiting: 
   acute phase:  
      G1: 10/19 (62.5%) 
      G2: 7/10 (70%) 
   delayed phase:  
      G1: 12/16 (75%) 
      G2: 6/16 (37.5%) 
 
Proportion with complete control of nausea: 
   acute phase:  
      G1: 5/19 (26%) 
      G2: 7/16 (43.75%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Smith 
(1991)[29] 
 
 Prospective open-label trial 
 Aim: Assess the efficacy of 
ondansetron  for antiemetic 
prophylaxis in patients 
receiving carboplatin 
 N = 16 
 Adults with ovarian cancer 
receiving carboplatin 
 Median age: 58yrs; range: 23-
73yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
highly emetogenic 
>2 emetic episodes in the 24hrs following carboplatin 
 
Previous prophylactic regimen: 
Days 1: dexamethasone 8mg PO tid + metoclopramide 20mg 
PO qid beginning prior to chemo 
 
Guideline consistent antiemetic prophylaxis: no 
 
Ondansetron 4mg IV and 4mg PO prior to 
chemo, then 8mg PO tid x 5 days 
Proportion with complete control of vomiting: 
   acute phase: 11/16 (69%) 
   acute and delayed phases     
      (days 1-5): 6/16 (46%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24hr x 5 days) 
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5HT-3 Antagonists – Palonosetron 
Hesketh 
(2012)[30] 
 
 Prospective open-label trial 
 Aim: Determine the efficacy 
and safety of a single IV dose of 
palonosetron for prevention of 
CINV  
 N = 34 
 Adults with cancer receiving  
chemotherapy who 
experienced refractory CINV 
 Mean age: 64.6 ± 13.77yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
low emetogenicity 
Vomiting and/or at least moderate nausea during cycle 1 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Day 1: Palonosetron 0.25mg IV 30min prior 
to chemo 
 
Proportion with complete control of vomiting: 
   acute phase: 31/34 (91.2%) 
   delayed phase: 27/34 (79.4%) 
 
Proportion with complete control of nausea: 
    acute phase: 25/34 (73.5%) 
   delayed phase: 18/34 (52.9%) 
 
Proportion with complete control of CINV 
(defined as no emetic episodes, no rescue 
medications and no more than mild nausea):  
   acute phase: 29/34 (85.3%) 
   delayed phase: 22/34 (64.7%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Massa 
(2009)[31] 
 
 Prospective open label trial  
 Aim: Determine if palonosetron 
is able to prevent CINV in 
refractory patients  
 N = 47 
 Adults with cancer receiving 
chemotherapy 
 Mean age: 60.7 ± 3yrs; range: 
32-89yrs  
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Grade 3-4 CINV during the first course of chemo that failed to 
respond to a different 5-HT3 antagonist 
 
Previous prophylactic regimen: 
D1: 5-HT3 antagonist (granisetron 1mg IV or ondansetron 8mg 
IV) + dexamethasone 8mg or 12mg IV 
D2-3 or 4: Dexamethasone 8mg PO 
 
Guideline consistent antiemetic prophylaxis: yes for MEC, no 
for HEC 
 
D1: Palonosetron 0.25mg IV + 
dexamethasone 16mg IV 
D2-3: Dexamethasone 8mg IV q12h 
D4: Dexamethasone 4mg IV q12h 
± metoclopramide IM prn 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV 
(defined as no emetic episodes, no rescue 
medications and no more than mild nausea): 
   acute phase: 36/47 (76.6%) 
   delayed phase: 38/47 (80.9%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
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5HT-3 Antagonists – Tropisetron 
Bruntsch 
(1993)[32] 
 
 Prospective, randomized, open-
label trial 
 Aim: Determine the efficacy of 
tropisetron in refractory 
patients compared to 
conventional antiemetic 
treatment 
 N = 115 
 Adults with cancer receiving 
chemotherapy 
 Mean age: 49 yrs 
 CINV assessment: patient 
report plus report by  an 
additional individual for the 
first 24hrs 
 Emetogenicity classification: 
low, moderate and highly 
emetogenic agents  
≥ 3 vomiting episodes within 24hrs during previous chemo 
cycles 
 
Previous prophylactic regimen: individually prescribed for 
each patient by investigator  
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Tropisetron 5mg IV/PO beginning the day 
before chemo and continuing for at least 5 
days (duration dependent on duration of 
chemo) 
Proportion with complete control of vomiting:  
   acute phase: 60/115 (52%) 
 
Proportion with complete control of nausea: 
   acute phase: 37/115 (32%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 6 days) 
Falkson 
(1995)[33] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
efficacy and safety of 
tropisetron in refractory 
patients 
 N = 164 
 Adolescents and adults with 
cancer receiving chemotherapy 
 Median age: 48yrs; range: 14-
88yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately emetogenic 
≥ 5 nausea and vomiting episodes despite antiemetic 
treatment during previous courses of chemo 
 
Previous prophylactic regimens: 
G1: Ondansetron: 46 pts 
G2: Granisetron: 39 pts 
G3: Metoclopramide: 40 pts 
G4: Chlorpromazine: 15 pts 
G5: Prochlorperazine: 13 pts 
G6: Cyclizine: 6 pts 
G7: Hydroxyzine: 5 pts 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Day 1: Tropisetron 5mg IV  
Days 2-5: Tropisetron 5mg PO once daily 
Proportion with complete control of vomiting: 
   acute phase: 29/81 (36%) 
   delayed phase: 33/81 (41%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV:  
   acute phase: 69/164 (42%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
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Fosaprepitant 
Covens 
[abstract] 
(2014)[34] 
 
 Prospective open-label study 
 Aim: Demonstrate that 
fosaprepitant improves 
vomiting control  
 N= 106 
 Adults with breast or 
gynaecological cancer with 
refractory CINV in the first cycle 
 Median age: 45 yrs (breast 
cancer); 55 yrs (gynaecological 
cancer) 
 CINV assessment: not reported 
 Emetogenicity: moderately or 
highly emetogenic 
Vomiting or retching during the first 5 days in cycle 1. 
 
Previous prophylactic regimen: 
not reported 
 
Guideline consistent antiemetic prophylaxis: 
unable to determine 
Not reported Proportion with complete control of vomiting 
and retching: 58% 
 
Timeframe of assessments: within first 120 
hours after initiation of chemotherapy  
Aprepitant 
Abbrederis 
(2009)[35] 
 
 Prospective open-label trial 
 Aim: evaluate the incidence of 
CINV during treatment of 
gastrointestinal tumors with 
chemotherapy and assess the 
effect of aprepitant after 
failure of first line antiemetic 
prophylaxis 
 N = 7 
 Adults with gastrointestinal 
tumors 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
CINV ≥ grade 2 (NCI definition) during the first course of 
chemo 
 
Previous prophylactic regimen: 
Day 1: Granisetron 1.5mg IV + dexamethasone 12mg IV 
Days 2-3: Dexamethasone 8mg PO once daily 
 
Guideline consistent antiemetic prophylaxis: yes for MEC, no 
for HEC 
Day 1: Aprepitant 125mg PO   
Days 2-3: Aprepitant 80mg PO  
+ previous prophylactic regimen described  
 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with “complete relief” from CINV 
(assumed to be complete control): 5/7 (71%) 
p=0.096 
 
Timeframe of assessments: not reported 
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Caranana  
[abstract] 
(2013) [36] 
 
 Prospective open-label trial 
 Aim: Evaluate efficacy of 
aprepitant in addition to 
standard antiemetic 
prophylaxis 
 N = 24 
 Adults with breast cancer 
receiving docetaxel 75mg/m
2
 + 
cyclophosphamide 600mg/m
2
 
IV with refractory CINV in the 
first cycle 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient diary 
and Functional Living Index-
Emesis questionnaire 
 Emetogenicity classification: 
moderately emetogenic 
Vomiting or receipt of rescue antiemetic therapy despite 
prophylaxis with a 5-HT3 antagonist and dexamethasone in 
cycle 1 
 
Previous prophylactic regimen: 
Day 0: dexamethasone 8mg PO at night 
Day 1: dexamethasone 8mg TID PO + 5-HT3 antagonist 
Day 2 and 3: dexamethasone 8mg BID PO 
 
Guideline consistent antiemetic prophylaxis: 
no 
Day 1: Aprepitant 125mg PO  
Days 2-3: Aprepitant 80mg PO once daily  
+ previous prophylactic regimen described 
 
Previous dexamethasone dose was reduced 
by 50%. 
Proportion with complete control of vomiting 
and no use of rescue antiemetic  treatment: 
14/24 (56%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: within first 120 
hours after initiation of chemotherapy 
Fukazawa 
(2011)[37] 
 
 Trial design: Prospective, open-
label trial 
 Aim: evaluate the effect of 
aprepitant on acute and 
delayed nausea and vomiting 
 N = 13 
 Adults with colorectal cancer 
receiving chemotherapy 
 Mean age: 65±11yrs  
 CINV assessment: Patient 
report (diary) 
 Emetogenicity classification: 
moderately emetogenic 
Definition: Delayed CINV occurring in the previous 
chemotherapy block 
 
Previous prophylactic regimen: 
Granisetron 3mg IV + dexamethasone 8mg IV 30-60min pre-
chemo 
 
Guideline consistent antiemetic prophylaxis: yes 
Day 1: Aprepitant 125mg PO + granisetron 
3mg IV + dexamethasone 4mg IV 30-60min 
pre-chemo 
Days 2-3: Aprepitant 80mg PO 1 hr pre-
chemo 
 
Proportion with complete control of vomiting: 
   acute phase: 13/13 (100%) 
   delayed phase: 13/13 (100%) 
 
Proportion with complete control of nausea: 
   acute phase: 10/13 (76.9%) 
   delayed phase: 6/13 (46.2%),   
      p<0.05 
 
Proportion with complete control of CINV 
(defined as no emesis, no rescue therapy, and 
no significant nausea):  
   acute phase: 12/13 (92.3%) 
   delayed phase: 9/13 (69.2%)   
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
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Hesketh 
(2009)[38] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
activity of aprepitant when 
used as salvage antiemetic 
therapy 
 N = 44 
 Adults with breast cancer 
receiving anthracycline 
+cyclophosphamide  
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately emetogenic 
Any vomiting, nausea, or use of rescue antiemetic 
medications during cycle 1 
 
Previous Prophylactic regimen: 
Day 1: A 5-HT3 antagonist (ondansetron 8mg IV or 24mg PO, 
dolasetron 100mg IV or PO, or granisetron 1mg IV or 2mg PO) 
+ dexamethasone 8-10mg IV or PO  
Days 2-3: Dexamethasone 4mg PO bid 
 
Guideline consistent antiemetic prophylaxis: yes 
 
Day 1: Aprepitant 125mg PO + a 5-HT3 
antagonist + dexamethasone 8-10mg IV or 
PO 
Days 2-3: Aprepitant 80mg PO + 
dexamethasone 4mg PO once daily 
 
Proportion with complete control of vomiting 
(acute and delayed phases): 36/44 (82%) 
 
Proportion with complete control of nausea 
(acute and delayed phases): 8/44 (18%) 
 
Proportion with complete control of CINV 
(including no use of rescue antiemetics): 
   acute phase: 13/44 (30%) 
   delayed phase: 10/44 (23%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Hu (2014) 
[39] 
 
 Prospective open-label study 
 Aim: Evaluate effectiveness of 
aprepitant in addition to 
standard antiemetic 
prophylaxis 
 N = 25 
 Adults with cancer receiving 
cisplatin 75mg/m2/dose with 
refractory CIV in the first cycle 
 Median age: 61 yrs (range: 32 
to 72 yrs) 
 CINV assessment: patient diary 
 Emetogenicity: highly 
emetogenic 
Vomiting greater than or equal to NCI-CTCAEv3.0 and receipt 
of rescue antiemetic therapy despite prophylaxis with 
granisetron and dexamethasone in cycle 1 
 
Previous prophylactic regimen: 
Day 1: granisetron 3mg IV x 1 dose and dexamethasone 10mg 
IV x 1 dose 
Day 1-3: metoclopramide 10mg TID PO and dexamethasone 
1.5mg TID PO 
 
Guideline consistent antiemetic prophylaxis: 
no 
Day 1: Aprepitant 125mg PO  
Days 2-3: Aprepitant 80mg PO once daily  
+ previous prophylactic regimen described 
 
Dexamethasone dose was not reduced. 
Proportion with complete control of vomiting 
and no use of rescue antiemetic treatment: 
16/25 (64%) 
 
Proportion with complete control of nausea:  
  acute phase: 6/8 (75%) 
  delayed phase: 7/25 (28%) 
 
Proportion with complete control of CINV: 
7/25 (28%) 
 
Timeframe of assessments: within first 120 
hours after initiation of chemotherapy 
Oechsle 
(2006)[40] 
 
 Prospective open-label trial 
 Aim: evaluate the efficacy of 
the addition of aprepitant in 
refractory patients 
 N = 34 
 Adults with cancer receiving 
chemotherapy 
 Median age: 51yrs; range: 23-
77yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
At least 2 days of nausea and/or emesis considered 
intolerable by the patient despite the use of guideline-based 
antiemetic standard prophylaxis 
 
Previous prophylactic regimen: 
Acute: Granisetron 1-3mg IV once daily + dexamethasone 4-
8mg IV at least twice daily or 20mg IV once daily on the days 
of chemo 
Delayed: Dexamethasone 4mg IV/PO bid + metoclopramide 
10mg PO tid x 3 days after completion of chemo 
 
Guideline consistent antiemetic prophylaxis: yes For MEC, no 
for HEC 
Day 1: Aprepitant 125mg PO + granisetron 
1-3mg IV + dexamethasone 4-8mg IV/PO x 2 
doses 
All further days of chemo: Aprepitant 80mg 
PO + granisetron 1-3mg IV + dexamethasone 
4-8mg IV/PO bid 
Days 2-3 after chemo: Aprepitant 80mg PO + 
dexamethasone 4mg PO bid + 
metoclopramide 20mg PO tid 
Proportion with complete control of vomiting 
(acute and delayed phases): 26/34 (76.5%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days after the last dose of 
chemo) 
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Wu 
(2012)[41] 
 
 Prospective open-label trial 
 Aim: Evaluate aprepitant as 
secondary antiemetic 
prophylaxis   
 N = 40 
 Adults with cancer receiving 
cisplatin + 5-fluorouracil ± 
other chemotherapy with 
refractory CINV 
 Median age: not reported for 
refractory cohort 
 CINV assessment: investigator 
(physicians and nurses) and 
patient report 
 Emetogenicity classification: 
highly emetogenic 
Failure to achieve complete protection from vomiting with a 
5-HT3 antagonist and dexamethasone in cycle 1 
 
Previous prophylactic regimen: 
Day 1: Granisetron 3mg IV + dexamethasone 20mg IV ± 
diphenhydramine 30mg IM q6h prn 
Additional days chemo was administered: Dexamethasone 
5mg IV q12h ± diphenhydramine 30mg IM q6h prn 
 
Guideline consistent antiemetic prophylaxis: no 
 
Day 1: Aprepitant 125mg PO  
Days 2-3: Aprepitant 80mg PO once daily  
+ previous prophylactic regimen described 
 
 
Proportion with complete control of vomiting: 
   acute phase: 39/40 (97.5%) 
   delayed phase: 26/40 (65%) 
 
Proportion with complete control of nausea: 
   acute phase: 37/40 (92.5%) 
   delayed phase: 24/40 (60%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 6 days) 
Benzodiazepines (Clonazepam, Lorazepam, and Midazolam) 
Hayashi 
(2010)[42] 
 
 Prospective open-label trial 
 Aim: Evaluate the efficacy of 
clonazepam in preventing CINV 
in refractory patients 
 N = 7 (10 chemotherapy 
courses) 
 Adults with cancer receiving 
cisplatin-based chemotherapy 
 Median age: 61yrs; range: 43-
73yrs 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
highly emetogenic 
Vomiting despite conventional antiemetic therapy 
 
Previous prophylactic regimen: 
Day 1: Granisetron 3mg IV + dexamethasone 12mg IV 60min 
prior to chemo 
Days 2-4: Dexamethasone 4mg IV once daily 
 
Guideline consistent antiemetic prophylaxis: no 
 
Day -1: Clonazepam 0.5mg or 1mg PO 
beginning 12hrs prior to chemo 
Days 1-4: Clonazepam 0.5mg or 1mg PO 
once daily  
+ previous prophylactic regimen described 
 
Proportion of cycles with complete control of 
vomiting: 
   acute phase: 8/10 (80%) 
   delayed phase: 6/10 (60%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Mandala 
(2005)[43] 
 
 Prospective open-label trial 
 Aim: evaluate the efficacy of 
the addition of midazolam to 
dexamethasone and 
granisetron for refractory acute 
CINV 
 N = 26 
 Adults with cancer receiving 
cisplatin-based chemotherapy 
 Median age: 58yrs; range: 30-
70yrs 
 CINV assessment: patient 
report and physician 
assessment 
 Emetogenicity classification: 
highly emetogenic 
Grade 2 acute nausea (oral intake significantly reduced) 
and/or vomiting (2-5 emetic episodes in 24hrs) 
 
Previous prophylactic regimen: 
Day 1: Granisetron 3mg IV + dexamethasone 20mg IV 
Days 2-5: Dexamethasone 4mg PO once daily + 
metoclopramide 20mg PO tid 
 
Guideline consistent antiemetic prophylaxis: no 
 
Midazolam 0.04mg/kg continuous infusion 
during administration of chemo + previous 
prophylactic regimen described 
Proportion with complete control of vomiting:  
   acute phase: 6/26 (23%) 
   delayed phase: 9/26 (34.6%) 
 
Proportion with complete control of nausea: 
   acute phase: 5/26 (19.2%) 
   delayed phase: 6/26 (23%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute and delayed 
phases (q24h, duration not reported) 
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Mughal  
(1983)[44] 
 
 Prospective open-label trial 
 Aim: Evaluate the antiemetic 
efficacy of lorazepam in 
patients who failed to benefit 
from standard antiemetics 
 N = 24 
 Adolescents and adults with 
lymphoma receiving 
chemotherapy 
 Age range: 14-60yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Severe vomiting for several hrs after chemo ± anticipatory 
vomiting 
 
Previous prophylactic regimen: 
Prochlorperazine 10-15mg/m2 IV ± metoclopramide 10-
15mg/m
2
 IV 
 
Guideline consistent antiemetic prophylaxis: no 
 
Lorazepam 3mg/m
2 
PO 30min prior to 
chemo + prochlorperazine 10mg IV 
Proportion with complete control of vomiting: 
17/24 (71%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute phase (1-
2hrs after chemo) 
Dexamethasone 
Aapro 
(1981)[45] 
 
 Prospective open-label trial 
 Aim: Evaluate high-dose 
dexamethasone for CIV 
 N = 10 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
unable to determine/not 
reported (28 patients received 
highly emetogenic 
chemotherapy) 
Previous failure to respond to other antiemetics 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
Dexamethasone 8mg PO the night before 
chemo, then dexamethasone 4mg PO q4-6h 
on the day of treatment + dexamethasone 
10mg IV prior to chemo ± droperdiol or 
haloperidol 2-2.5mg IV 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV 
(defined as no symptoms or slight nausea): 
3/10 (30%) 
 
Timeframe of assessments: not 
reported/unable to determine 
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Joss 
(1994)[46] 
 
 Randomized, double-blind trial 
 Aim: Assess whether the 
addition of dexamethasone 
leads to improved control of 
CINV 
 N = 96 
 Adults with cancer receiving 
chemotherapy 
 Median age:  
G1: 44yrs; range: 17-79yrs 
G2: 52yrs; range: 17-69yrs 
 CINV assessment: patient 
report (daily) and nursing 
assessment (first 24 hrs) 
 Emetogenicity classification: 
unable to determine/not 
reported 
> 5 vomiting episodes over 24hrs 
 
Previous prophylactic regimen: 
Day 1: Ondansetron 8mg IV x 3 doses  
Days 2-5: Ondansetron 8mg PO once daily 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
G1: Placebo 
G2: Day 1: Dexamethasone 20mg IV once 
       Days 2-5: Dexamethasone 4mg PO tid      
+ previous prophylactic regimen described 
 
Patients receiving multiple-days of chemo 
received IV antiemetics on the days of 
chemo and PO treatment as described 
afterward 
Proportion with complete control of vomiting: 
   acute phase:  
      G1: 25/52 (48.1%) 
      G2: 31/44 (70.5%)  
      (p = 0.03) 
 
Proportion with complete control of nausea: 
   acute phase:  
      G1: 22/52 (42.3%) 
      G2: 27/44 (61.3%)  
      (p = 0.06) 
 
Proportion with complete control of CINV: 
   acute phase:  
      G1: 18/52 (34.6%) 
      G2: 24/44 (54.5%)  
      (p = 0.05) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
Prochlorperazine 
Johansson 
(1982)[47] 
 
 Randomized, double-blind, 
cross-over trial 
 Aim: Compare the antiemetic 
efficacy of nabilone to 
prochlorperazine 
 N = 18 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
highly emetogenic 
Uncontrolled nausea and vomiting despite use of standard 
antiemetic drugs 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
G1: Nabilone 2mg PO bid x 4 doses 
G2: Prochlorperazine 10mg PO bid x 4 doses 
Proportion with complete control of vomiting:  
   G1: 3/18 (17%) 
   G2: 0/18 (0%) 
 
Proportion with complete control of nausea:  
   G1: 3/18 (17%) 
   G2: 0/18 (0%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute phase (q24h 
x 2 days) 
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McCabe  
(1988)[48] 
 
 Randomized, cross-over trial 
 Aim: Compare the antiemetic 
activity of THC versus 
prochlorperazine in refractory 
patients 
 N = 36 
 Adults with cancer receiving 
chemotherapy 
 Median age: 48yrs; range: 18-
69yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Severe nausea and vomiting refractory to standard 
antiemetics 
 
Previous prophylactic regimen: 
Prochlorperazine: 34 pts 
Thiethylperazine: 2 pts 
 
Guideline consistent antiemetic prophylaxis: no 
 
G1: THC 15mg/m
2
 PO prior to chemo then 
q4h for 24hrs 
G2: Prochlorperazine 10mg PO prior to 
chemo then q4h for 24hrs 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
   acute phase: 
      G1: 9/36 (25%) 
      G2: 0/36 (0%) 
 
Timeframe of assessments: acute phase (over 
24hrs) 
THC Compounds (Levonantradol, Nabilone, Tetrahydrocannabinol) 
Cronin 
(1981)[49] 
 
 Prospective open-label trial 
 Aim: Evaluate the effectiveness 
of IM levonantradol in 
refractory patients 
 N = 28 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported for 
evaluable patients (33yrs; 
range: 11-68yrs for all 31 
patients initially enrolled) 
 CINV assessment: patient 
report and investigator 
monitoring  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Refractory to the aggressive use of conventional antiemetic 
therapy 
 
Previous prophylactic regimen: 
Parenteral phenothiazines  
 
Guideline consistent antiemetic prophylaxis: no 
 
Levonantradol 0.5mg, 1mg, or 1.5mg IM 
q4h 
 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
5/28 (18%) 
 
Timeframe of assessments: acute phase (over 
24hrs) 
Diasio 
(1981)[50] 
 
 Prospective open-label trial 
 Aim: Report on the antiemetic 
efficacy of levonantradol in 
refractory patients 
 N = 22 (26 courses of 
chemotherapy) 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report and nurse monitoring  
 Emetogenicity classification: 
unable to determine/not 
reported  
Moderate to severe nausea and vomiting unrelieved by 
standard antiemetics 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
G1: Levonantradol 0.5mg PO q4h x 3-27 
doses (n=14) 
G2: Levonantradol 1mg PO q4h x 3-27 doses 
(n=11) 
G3: Levonantradol 1.5mg PO q4h x 3-27 
doses (n=11) 
 
Proportion of courses with complete control of 
vomiting:  
   G1: 1/14 (7%) 
   G2: 3/11 (27%) 
   G3: 0/1 (0%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute phase (4hrs 
following administration of levonantradol) 
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Gerhartz 
(1983)[51] 
 
 Prospective open-label trial 
 Aim: Report on experience with 
levonantradol in refractory 
patients 
 N = 20 
 Adults with cancer receiving 
chemotherapy 
 Mean age: 43yrs; range 19-
63yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Severe CINV despite conventional antiemetic therapy 
 
Previous prophylactic regimen: 
Levomepromazine 50mg IV/PO ± metoclopramide 10mg ± 
triflupromazine ± dimenhydrinate pre-chemo 
 
Guideline consistent antiemetic prophylaxis: no 
 
Levonantradol 0.5-1mg SC 30min prior to 
chemo ± additional doses 4-8hrs later  
Proportion with complete control of vomiting: 
8/20 (40%) 
 
Proportion with complete control of nausea: 
5/20 (25%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: unable to 
determine/not reported (pts reported on their 
experience when the experimental cycle was 
finished)  
Heim 
(1982)[52] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
efficacy of levonantradol 
 N = 20  
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported; 
range: 19-66yrs 
 CINV assessment: Patient 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
“Patients treated without sufficient success of nausea and 
vomiting when treated with other antiemetics” 
 
Previous prophylactic regimen: 
Meclizine, metoclopramide, haloperidol, triflupromazine, 
flupentixol, and/or levomepromazine 
 
Guideline consistent antiemetic prophylaxis: no 
 
Levonantradol 1mg (0.5mg for patients 
weighing less than 50kg) IM 8hrs prior to 
chemo, then the same dose repeated at 2hrs 
and 6hrs post-chemo 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
5/20 (25%) 
 
Timeframe of assessments: acute phase (q24h 
x 2 days) 
Herman 
(1977)[53] 
 
 Prospective open-label trial 
 Aim: Determine the antiemetic 
efficacy of nabilone and 
evaluate side effects 
 N = 13 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported 
 CINV assessment: patient 
report 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Severe nausea and vomiting from chemo not controlled by 
standard antiemetics 
 
Previous Prophylactic regimen: 
Prochlorperazine 
 
Guideline consistent antiemetic prophylaxis: no 
 
Nabilone 1-2mg PO q8h x 5 days with 2 
doses administered prior to chemo 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV 
(defined as an average daily rating of zero for 
nausea and vomiting): 2/13 (15%) 
 
Timeframe of assessments: acute and delayed 
phases (q24h x 5 days) 
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Johansson 
(1982)[47] 
 
 Randomized, double-blind, 
cross-over trial 
 Aim: Compare the antiemetic 
efficacy of nabilone to 
prochlorperazine 
 N = 18 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
highly emetogenic 
Uncontrolled nausea and vomiting despite use of standard 
antiemetic drugs 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
G1: Nabilone 2mg PO bid x 4 doses 
G2: Prochlorperazine 10mg PO bid x 4 doses 
Proportion with complete control of vomiting:  
   G1: 3/18 (17%) 
   G2: 0/18 (0%) 
 
Proportion with complete control of nausea:  
   G1: 3/18 (17%) 
   G2: 0/18 (0%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: acute phase (q24h 
x 2 days) 
Laszlo 
(1981)[54] 
 
 Prospective open-label trial 
 Aim: Evaluate the effectiveness 
of parenteral levonantradol in 
refractory patients 
 N = 33 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported for 
refractory cohort 
 CINV assessment: patient 
report and investigator 
monitoring  
 Emetogenicity classification: 
unable to determine/not 
reported 
Persistent nausea and vomiting despite the use of standard 
antiemetics 
 
Previous prophylactic regimen: 
PO or parenteral phenothiazines ± additional prn antiemetics 
 
Guideline consistent antiemetic prophylaxis: no 
 
Levonantradol 0.5mg, 1mg, 1.5mg, or 2mg 
PO q4h x 3-27 doses  
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
3/33 (9%) 
 
Timeframe of assessments: acute phase (over 
the course of chemo) 
Lucas  
(1980)[55] 
 
 Prospective open-label trial 
 Aim: Determine if PO THC is an 
effective antiemetic for 
refractory patients 
 N = 53 
 Adults with cancer receiving 
chemotherapy 
 Median age: 51yrs; range: 18-
69yrs) 
 CINV assessment: patient 
report and investigator 
monitoring  
 Emetogenicity classification: 
unable to determine/not 
reported 
 
 
 
 
 
Persistent severe nausea and vomiting in spite of aggressive 
use of standard antiemetics 
 
Previous Prophylactic regimen: 
“Drug therapy” beginning 10-12hrs prior to chemo and 
continuing throughout the course of chemo, ± additional 
doses of antiemetics  
 
Guideline consistent antiemetic prophylaxis: no 
 
Δ9-tetrahydrocannabinol 15mg/m2 PO q6h 
x 4 doses beginning 1hr prior to chemo OR 
5mg/m2 PO q4h beginning 8-12hrs prior to 
chemo and continuing for 24hrs after chemo 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
10/53 (19%) 
 
Timeframe of assessments: not 
reported/unable to determine (pts observed 
by investigators over the course of chemo) 
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McCabe  
(1988)[48] 
 
 Randomized, cross-over trial 
 Aim: Compare the antiemetic 
activity of THC versus 
prochlorperazine in refractory 
patients 
 N = 36 
 Adults with cancer receiving 
chemotherapy 
 Median age: 48yrs; range: 18-
69yrs 
 CINV assessment: patient 
report  
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Severe nausea and vomiting refractory to standard 
antiemetics 
 
Previous prophylactic regimen: 
Prochlorperazine: 34 pts 
Thiethylperazine: 2 pts 
 
Guideline consistent antiemetic prophylaxis: no 
 
G1: THC 15mg/m
2
 PO prior to chemo then 
q4h for 24hrs 
G2: Prochlorperazine 10mg PO prior to 
chemo then q4h for 24hrs 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
   acute phase: 
      G1: 9/36 (25%) 
      G2: 0/36 (25%) 
 
Timeframe of assessments: acute phase (over 
24hrs) 
Stambaugh 
(1984)[56] 
 
 Randomized, double-blind, 
placebo-controlled trial 
 Aim: Evaluate the efficacy and 
toxicity of intramuscular 
levonantradol 
 N = 20 
 Adults with cancer receiving 
chemotherapy 
 Median age: not reported 
 CINV assessment: patient and 
observer report  
 Emetogenicity classification: 
unable to determine/not 
reported 
Persistent nausea and vomiting from chemo refractory to 
maximally recommended doses of conventional antiemetics 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported  
 
Levonantrodol 0.5mg, 1mg, 1.5mg, or 2mg 
IM 2hrs prior to chemo then q4h for 3 
additional doses 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
 acute phase: 11/20 (55%) 
 
Timeframe of assessments: acute phase (over 
24hrs) 
Stuart-
Harris 
(1983)[57] 
 
 Prospective open-label trial 
 Aim: Determine the efficacy of 
levonantradol for CINV in 
refractory patients 
 N = 22 
 Adults with cancer receiving 
chemotherapy 
 Median age: 49yrs; range 20-
70yrs 
 CINV assessment: patient 
report and nurse monitoring  
 Emetogenicity classification: 
unable to determine/not 
reported (6 patients received 
highly emetogenic 
chemotherapy) 
 
 
 
 
 
Severe nausea and vomiting refractory to conventional 
antiemetic treatment 
 
Previous prophylactic regimen: 
Chlorpromazine 50-100mg IV/IM q4-6h: 13 pts 
Prochlorperazine 12.5-25mg IV q4-6h: 12 pts 
Metoclopramide 10-15mg IV q4h: 5 pts 
Thiethylperazine 10mg suppositories q6h: 2 pts 
Perphenazine 6mg PO q8h: 1 pt 
 
Guideline consistent antiemetic prophylaxis: no 
Levonantradol 0.5mg IM 1 hour pre-chemo 
± additional doses q4h prn 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
3/22 (13.6%) 
 
Timeframe of assessments: not 
reported/unable to determine 
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Miscellaneous (Methotrimeprazine, Medroxyprogesterone, and Propofol) 
Borgeat 
(1994)[58] 
 
 Prospective open-label trial 
 Aim: Determine the efficacy 
and safety of added low-dose 
propofol infusion in patients 
experiencing refractory CINV  
 N = 20 
 Adults with breast cancer 
receiving non-cisplatin 
chemotherapy 
 Median age: 56yrs; range: 45-
72yrs 
 CINV assessment: nurse report 
 Emetogenicity classification: 
moderately emetogenic 
> 5 emetic episodes in the first 24hrs despite antiemetic 
prophylaxis during their first cycle of chemo 
 
Prophylactic regimen: 
Ondansetron 8mg IV x 2 doses + dexamethasone 10mg IV once 
 
Guideline consistent antiemetic prophylaxis: yes 
 
Propofol 1mg/kg/hr continuous infusion 
started 4 hrs prior to chemo and continuing 
for 24 hrs + previous prophylactic regimen 
described  
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
   acute phase: 18/20 (90%) 
 
Timeframe of assessments: acute phase (q2h 
starting 4hrs pre-chemo and continuing for 24 
hrs after chemo) 
Borgeat 
(1993)[59] 
 
 Prospective open-label trial 
 Aim: Determine the efficacy 
and safety of added low-dose 
propofol infusion in patients 
experiencing refractory CINV  
 N = 20 
 Adults with cancer receiving 
cisplatin-based chemotherapy 
 Median age: 52yrs; range: 30-
70yrs 
 CINV assessment: nurse report 
 Emetogenicity classification: 
moderately emetogenic 
> 5 emetic episodes in the first 24hrs despite antiemetic 
prophylaxis during their first cycle of chemo 
 
Previous prophylactic regimen: 
Ondansetron 8mg IV OR granisetron 3mg IV x 3 doses + 
dexamethasone 10mg IV once 
 
Guideline consistent antiemetic prophylaxis: yes 
 
Propofol 1mg/kg/hr continuous infusion 
started 4 hours prior to chemo and 
continuing for 72hrs after + previous 
prophylactic regimen described 
 
Proportion with complete control of vomiting:  
   acute phase: 17/20 (85%) 
   delayed phase: 15/20 (75%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported  
 
Timeframe of assessments: acute and delayed 
phases (q2h starting 4hrs pre-chemo and 
continuing for 72hrs after chemo) 
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Hata 
(2012)[60] 
 
 Case series 
 Aim: Describe 3 cases where 
medroxyprogesterone acetate 
was effective for cisplatin-
induced refractory emesis 
 N = 3 
 Adults with cancer receiving 
cisplatin + gemcitabine 
 Median age: 58 yrs; range:58-
67yrs 
 CINV assessment: not reported 
 Emetogenicity classification: 
highly emetogenic 
Emesis occurring despite the use of antiemetic prophylaxis 
during the previous cycle  
 
Previous Prophylactic regimen: 
Pt 1: 
Day 1: Granisetron 3mg + aprepitant 125mg + dexamethasone 
12mg 
Days 2-3: Aprepitant 80mg + dexamethasone 8mg 
Day 4: Dexamethasone 8mg 
 
Pt 2:  
Day 1: Granisetron 1mg + aprepitant 125mg + dexamethasone 
8mg 
Days 2-3 and 9-10: Aprepitant 80mg + dexamethasone 4mg 
Day 8: Dexamethasone 8mg 
 
Pt 3:  
Day 1: Palonosetron 0.75mg + aprepitant 125mg + 
dexamethasone 12mg 
Days 2-3: Aprepitant 80mg + dexamethasone 8mg 
Day 4: Dexamethasone 8mg 
 
Guideline consistent antiemetic prophylaxis:  
Pt 1: yes 
Pt 2: yes 
Pt 3: yes 
Pt 1: 
Day 1: Granisetron 3mg + dexamethasone 
12mg 
Days 2-4: Medroxyprogesterone acetate 
900mg PO + dexamethasone 8mg 
Day 5: Medroxyprogesterone acetate 900mg 
PO 
 
Pt 2: 
Day 1: Granisetron 1mg + dexamethasone 
8mg 
Days 2-4: Medroxyprogesterone acetate 
900mg PO + dexamethasone 4mg 
Day 5: Medroxyprogesterone acetate 900mg 
PO 
 
Pt 3:  
Day 1: Palonosetron 0.75mg + aprepitant 
125mg + dexamethasone 12mg + 
Medroxyprogesterone acetate 900mg PO 
Days 2-3: Aprepitant 80mg + 
dexamethasone 8mg + 
Medroxyprogesterone acetate 900mg PO 
Day 4: Dexamethasone 8mg + 
Medroxyprogesterone acetate 900mg PO 
 
Proportion with complete control of vomiting: 
3/3 (100%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: not reported 
Higi 
(1980)[61] 
 
 Prospective open-label trial  
 Aim: Determine the antiemetic 
efficacy of oral 
methotrimeprazine  
 N = 113 
 Adults with cancer receiving 
either cisplatin, ifosfamide, or 
adriamycin-containing 
chemotherapy combinations 
 Median age: not reported  
 CINV assessment: clinical 
observation 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
 
 
 
 
 
Refractory to conventional antiemetics 
 
Previous prophylactic regimen: 
Metoclopramide ± triflupromacine ± other 
phenothiazines/antihistamines 
 
Guideline consistent antiemetic prophylaxis: no 
 
Methotrimeprazine 8-15mg PO x 2 doses 
beginning 12hrs and 60 min prior to chemo 
Proportion with complete control of vomiting: 
not reported 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: 
70/113 (62%) 
 
Timeframe of assessments: not 
reported/unable to determine 
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First 
Author 
(Year) 
Study Design, Objective and 
Population 
Definition of Refractory CINV and CINV Prophylaxis 
Provided During Previous Chemo Blocks 
Antiemetic Interventions 
Proportion with Complete Control of 
Refractory Nausea and/or Vomiting 
Non-pharmacological Interventions - Acupressure/Acupuncture 
Choo 
(2006)[62] 
 
 Prospective open-label trial 
 Aim: evaluate the efficacy of 
electroacupuncture in 
preventing refractory CINV 
 N = 27 
 Adults with cancer receiving 
anthracycline-based 
chemotherapy for breast 
cancer 
 Median age: 48yrs; range: 37-
60yrs 
 CINV assessment: patient 
report and physician 
assessment 
 Emetogenicity classification: 
moderately emetogenic 
More than 2 episodes of emesis occurring in the first 24hrs 
after chemo when antiemetic prophylaxis and rescue 
antiemetics were given 
 
Previous prophylactic regimen: 
Day 1: A 5-HT3 antagonist (ondansetron 8mg IV or granisetron 
3mg IV) + dexamethasone 8mg IV 
Days 2-3: A 5-HT3 antagonist PO 
Breakthrough medications including PO metoclopramide, 
lorazepam and dexamethasone permitted 
 
Guideline consistent antiemetic prophylaxis: yes 
 
Electroacupuncture at PC6 for 30min 
beginning 10min prior to chemo + previous 
prophylactic regimen described 
Proportion with complete control of vomiting: 
10/27 (37%) 
 
Proportion with complete control of nausea: 
3/27 (11%) 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: not reported 
Gardani 
(2007)[63] 
 
 Prospective open-label trial 
 Aim: evaluate the efficacy of 
PC6 stimulation by acupressure 
for the treatment of refractory 
CIV 
 N = 100 
 Adults with solid tumors 
 Median age: 59yrs 
 CINV assessment: not reported 
 Emetogenicity classification: 
moderately or highly 
emetogenic 
Grade 3-4 vomiting and no response to “conventional 
antiemetics” including 5-HT3 antagonists, corticosteroids, and 
antidopaminergic agents 
 
Previous prophylactic regimen: not reported 
 
Guideline consistent antiemetic prophylaxis: unable to 
determine/not reported 
 
Stimulation of the PC6 acupoint by 
acupressure for 8hrs a day starting prior to 
chemo and continuing for at least 3 days 
after chemo 
Proportion with complete control of vomiting: 
68/100 (68%) 
 
Proportion with complete control of nausea: 
not reported 
 
Proportion with complete control of CINV: not 
reported 
 
Timeframe of assessments: not reported 
Emetogenicity classified according to the MASCC and ASCO guidelines 
*Prophylaxis considered “guideline consistent” in adult studies based on current recommendations provided by MASCC and/or ASCO and/or NCCN and on the POGO Acute 
AINV guideline for paediatric studies 
Complete control of vomiting = no vomiting, Complete control of nausea = no nausea, Complete control of CINV = no nausea or vomiting (unless defined otherwise) 
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Supplementary Table VII: Health questions, summary of recommendations and remarks for the treatment of 
breakthrough chemotherapy-induced nausea and vomiting (CINV) and the prevention of refractory CINV in children 
 
 
Health Questions and Recommendations 
Strength of 
Recommendation 
& Level of 
Evidence
9,10
 
Health Question #1:  What interventions are recommended to treat breakthrough CINV in 
children?  
Breakthrough CINV is defined as nausea and/or vomiting presumed to be attributable to antineoplastic 
chemotherapy and with no other pathological cause which occurs during the acute or delayed phase despite CINV 
prophylaxis. 
 
Recommendation 1.1: For children receiving acute CINV prophylaxis 
recommended for minimally, low, or moderately emetogenic 
chemotherapy, clinicians should upgrade or escalate the acute CINV 
prophylaxis provided to that recommended for chemotherapy of the next 
higher level of emetogenic risk.  
 
Remarks:  This recommendation places a high value on the possible 
control of breakthrough CINV in the acut  phase by provision of CINV 
prophylaxis (pharmacological and non-pharmacological) known to be 
effective in the setting of more emetogenic chemotherapy. It is a 
strong recommendation because the guideline panel is certain that 
the benefits of acute CINV prophylaxis escalation outweigh the low 
risk of harms associated with the interventions. 
 
Recommendation 1.2: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy, we suggest that 
olanzapine be added to guideline-consistent CINV prophylaxis. 
 
Remarks:  This recommendation places value on the high quality 
evidence of the efficacy of olanzapine as a therapeutic intervention in 
adults receiving contemporary CINV prophylaxis.  It is a weak 
recommendation because direct evidence of efficacy of olanzapine 
for prevention or treatment of CINV in children and of its safety in 
children receiving chemotherapy is limited.  Furthermore, the optimal 
pediatric dose for this indication is uncertain. 
 
Recommendation 1.3: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy and who cannot 
receive olanzapine,  we suggest that one of the following antiemetic 
agents be added to guideline-consistent CINV prophylaxis: 
 
 methotrimeprazine (also known as levomepromazine) 
or 
 
Strong 
Recommendation 
Very Low Quality 
Evidence 
 
 
 
 
 
 
 
 
 
 
Weak 
Recommendation 
 Low Quality 
Evidence 
 
 
 
 
 
 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
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 metoclopramide (in children older than 1 year) 
 
Given the possibility of extrapyramidal reactions with these agents, 
the risks and benefits of their use should be weighed carefully and 
co-administration of prophylaxis aimed at preventing 
extrapyramidal symptoms (EPS) should be considered. Patients and 
families should also be educated about the possible occurrence of 
EPS. 

Remarks: The panel recognizes that the evidence base for these 
agents in adult patients consists of older studies that were not 
conducted in the context of currently recommended CINV prophylaxis 
and is of low quality.  Despite these limitations and although direct 
evidence of efficacy of these agents for treatment of breakthrough 
CINV in children is not available, the guideline panel made a weak 
recommendation for use of these agents. The panel placed a high 
value on the possible benefit of these agents in the setting of CINV 
prophylaxis failure. A lower value was placed on the potential for 
toxicity secondary to these agents because EPS are generally 
amenable to intervention and, although it may be distressing if not 
anticipated, is short-lived.   
 
 
 
 
Health Question #2:  What interventions are recommended to prevent CINV in children who 
have refractory CINV?   
Refractory CINV is defined as nausea and/or vomiting presumed to be attributable to antineoplastic chemotherapy 
and with no other pathological cause which occurs during the acute or delayed phase despite CINV prophylaxis in 
patients who have experienced breakthrough CINV in a previous chemotherapy block.  
 
Recommendation 2.1:  For children receiving acute CINV prophylaxis 
recommended for minimally, low, or moderately emetogenic 
chemotherapy, clinicians should upgrade or escalate the acute CINV 
prophylaxis provided to that recommended for chemotherapy of the next 
higher level of emetogenic risk.   
 
Remarks:  This recommendation places a high value on the possible 
control of refractory CINV in the acute phase by provision of CINV 
prophylaxis (pharmacological and non-pharmacological) known to be 
effective in the setting of more emetogenic chemotherapy. It is a 
strong recommendation because the guideline panel is certain that 
the benefits of acute CINV prophylaxis escalation outweigh the low 
risk of harms associated with the interventions. 
 
Recommendation 2.2: For children receiving acute CINV prophylaxis 
recommended for highly emetogenic chemotherapy, we suggest that the 
5-HT3 antagonist given for CINV prophylaxis be changed from 
ondansetron or granisetron to palonosetron. In jurisdictions where 
palonosetron is not available, we suggest that granisetron be substituted 
 
Strong 
Recommendation 
Very Low Quality 
Evidence 
 
 
 
 
 
 
 
 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
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for ondansetron. 
 
Remarks: This recommendation places a high value on the improved 
CINV control seen in adult cancer patients receiving palonosetron and 
in adult patients receiving granisetron who have a genetic 
predisposition to a poor response to ondansetron at usual doses.  It 
places less value on drug cost in the scenario where less expensive 
alternatives have been ineffective. It is a weak recommendation 
because direct evidence of the comparative efficacy of palonosetron 
or of using an alternative 5HT-3 antagonist for prevention of 
refractory CINV in children is not available.   
 
Recommendation 2.3: For children experiencing refractory CINV despite 
initiation of previous recommendations and who have not previously 
received aprepitant because it is known or suspected to interact with the 
chemotherapeutic agent(s) being given, we suggest that the addition of 
aprepitant to acute CINV prophylaxis be considered.  
 
Remarks:  This recommendation places a high value on improved 
CINV control when control is likely to be difficult to achieve and on 
the negative consequences of uncontrolled CINV.  It is a weak 
recommendation since direct evidence of the efficacy of aprepitant in 
this context is lacking.  Furthermore, the relative risks of aprepitant 
(potential for drug interaction with chemotherapy and altered 
chemotherapy exposure) and benefits (CINV control) should be 
determined on a case-by-case basis. 
 
Recommendation 2.4: For children experiencing refractory CINV despite 
initiation of the previous recommendations, we suggest that one of the 
following interventions be added to the CINV prophylaxis provided: 
 
 interventions that were employed successfully for the treatment 
of breakthrough CINV in previous treatment blocks (olanzapine, 
methotrimeprazine or metoclopramide); or 
 
Remarks: This recommendation places a high value on the potential 
for continued CINV control using interventions that were used 
successfully and without significant adverse effects in patients who 
previously experienced breakthrough CINV.  It is a weak 
recommendation because the impact of the recommended action has 
not been evaluated. 
 
 stimulation of Nei Guan (P6) by means of acupressure or electro-
acupuncture. 
 
Remarks: This recommendation places a high value on the possibility 
that acupressure or electro-acupuncture may increase control of 
 
 
 
 
 
 
 
 
 
 
 
 
Weak 
Recommendation 
Low Quality 
Evidence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
 
 
 
 
 
 
 
Weak 
Recommendation 
Very Low Quality 
Evidence 
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CINV in patients who have experienced refractory CINV with a low 
potential for harm.  It is a weak recommendation because of 
imprecision of estimates, inability to evaluate consistency and 
indirectness since there is a single study to support the use of each 
intervention in adults and there is no direct information regarding the 
efficacy or safety of acupressure or electro-acupuncture in children 
with refractory CINV.   
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